R etrospective analysis of several studies suggested that heparin treatment might be beneficial in septic patients (1) (2) (3) (4) . In this issue of Critical Care Medicine, Jaimes et al (5) present the results of the first large, prospective randomized controlled trial of intravenous heparin for sepsis. Given at a fixed dose of 500 U/hr for up to 7 days, heparin vs. placebo had no significant beneficial effect on allcause mortality ( 20] vs. 12 days [6 -18] ). Importantly, bleeding risk was assessed daily by monitoring the activated partial thromboplastin time (aPTT). Possibly, as a result, there was no significant increase in bleeding associated with heparin, because any patient in the trial with an aPTT greater than 60 seconds (42 of 319 patients) had treatment terminated.
The authors should be commended for undertaking this large sepsis trial of heparin therapy and their efforts to maintain double blinding. However, there are several aspects of the trial that limit its interpretation. The population studied had a relatively low-control mortality rate (14%), and therefore, the results may not be applicable to more severely ill septic patients. In studies of other antithrombotic agents in sepsis, when benefit was found in subgroups, it was among patients with a higher risk of death (1, 6) . Also, the dose of heparin used by Jaimes et al was lower than standard therapeutic dose heparin (7) . Furthermore, despite this relatively low dose, a quarter of the patients treated with heparin (38 of 159) were still eliminated from the study (although included in the intention-to-treat analysis) before completing the 7 days trial because of an elevated aPTT. Thus, treatment may have been inadequate to achieve a beneficial effect in many patients. In contrast to this study, a recent retrospective analysis of higher risk septic patients reported that therapeutic dose heparin administered for concurrent problems and presumably adjusted (but not terminated) based on aPTT levels was associated with improved survival (8) .
Despite these potential limitations, Jaimes' prospective results add to those of three other antithrombotic agents questioning the pathogenic role of thrombosis in sepsis and the effectiveness of this therapeutic approach (1, 2, 4, 6, 9 -17) . Previously, recombinant human activated protein C (rhAPC), tissue factor pathway inhibitor, and antithrombin III were tested in Phase II and III trials. All showed no significant benefit except one testing rhAPC (1) . However, subsequent controlled trials of rhAPC in different septic populations (adults with a low risk of death and pediatric patients) did not show benefit (9, 16) . In part, because of these inconsistent effects, additional trials (PROWESS-Shock, RESPOND, and APROCCHS trials) (18 -20) testing rhAPC in high-risk adult septic patients are now underway and enrolling patients. These trials will hopefully help us understand why rhAPC seemed beneficial in the first but not subsequent Phase III trials.
Assuming, however, that thrombosis does indeed have an important role in the pathogenesis of sepsis, there are several reasons why heparin represents an antithrombotic agent that deserves further study. Although heparin was not beneficial in the study by Jaimes et al, it also did not increase the risk of bleeding. In con-trast to heparin, protocols to monitor bleeding risk and to adjust dosing accordingly are not readily available for the other three antithrombotic agents tested in sepsis, and each has been associated with increased bleeding in large trials (1, 2, 4, 9, 16) . Other reasons supporting an additional clinical trial of heparin in sepsis include the following: 1) it is relatively inexpensive; 2) it has been used extensively and successfully in other critical illnesses, such as deep venous thrombosis, pulmonary embolism, and acute coronary syndrome; 3) it has been shown to be highly effective at preventing thrombosis formation and accelerating its resolution; and 4) methods to adjust its dose on a weight basis have been well worked out to maximize benefit and minimize risk. Although similar dose adjustments might be possible for other antithrombotic agents, defining the appropriate measures and developing effective protocols to monitor and reduce their hemorrhagic risk would require substantial investigation.
On the basis of these reasons, we believe an additional large randomized controlled trial of heparin in sepsis is warranted. However, such a trial, in contrast to this one by Jaimes et al, should include a patient population with a higher risk of death and therapy should be adjusted based on therapeutic aPTT values as is conventionally done in other critical illnesses. Without such adjustment, undertreatment in some patients and overtreatment in others might negate any potential benefit of heparin for sepsis. In the absence of such a study, it is difficult to conclude that heparin has been fully tested and has no role in the treatment of sepsis. Importantly, patients with sepsis are a vulnerable group, and even with heparin therapy adjusted based on aPTT, the safety of such a study would have to be closely monitored.
Amisha V. Barochia (activated) in adult patients with septic shock. Available at: http://clinicaltrials.gov/ct2/show/NCT00604214. Accessed February 11, 2008 18 . Activated protein C and corticosteroids for human septic shock (APROCCHS). Available at: http://clinicaltrials.gov/ct2/show/NCT00625209. Accessed February 11, 2008 Stem cell therapy: A "magic bullet" for cardiomyopathies?* S tem cell transplantation is emerging as a promising new approach for the management of end-stage disease of the vital organs, including diseases of the liver (1), brain (2) , heart, and, perhaps, even kidney (3) . In the context of ischemic cardiomyopathy, animal studies (4) and a series of early human clinical trials (5, 6) show bone marrow-derived stem cell transplantation to be beneficial in terms of restoring cardiac function. It is shown that stem cells home to ischemic tissues and promote cardiac regeneration via both the differentiation of these cells into vasculogenic and myogenic lineage and through creation of local paracrine effects, which stimulate endogeneous reparative processes (7) . In this context, a large randomized placebo-controlled study of skeletal muscle myoblast transplantation performed at the time of coronary artery bypass grafting, the Myoblast Autologous Grafting in Ischemic Cardiomyopathy trial, showed only modest benefits in terms of left ventricular remodeling at the expense of a higher incidence of ventricular arrhythmias (8) . There are several potential explanations for the disappointing results of the Myoblast Autologous Grafting in Ischemic Cardiomyopathy study, including the inability to differentiate the benefits of transplantation from coronary artery bypass grafting, and the likelihood that the origin of the stem cell line (e.g., bone marrow vs. myoblast) is an important factor.
Even less is known about the effects of stem cells for the recovery of cardiac function in nonischemic cardiomyopathies (CMP), which is based on a limited number of studies in rodent models of nonischemic dilated cardiomyopathy (DCM) . Using an autoimmune model of myocarditis, Nagaya et al (7) showed that intramyocardial injection of bone marrow-derived mesenchymal stem cells, which were characterized by CD31-, CD29ϩ, and CD90ϩ surface marker expression, results in a significant improvement in cardiac performance and a reduction in cardiac fibrosis 4 weeks post-treatment. Immunohistochemical analyses demonstrated that the mesenchymal stem cells had differentiated into vascular endothelium, vascular smooth muscle cells, and cardiomyocytes. Likewise, in the context of congenital cardiomyopathy, embryonic stem cell therapy was shown to improve cardiac performance and led to partial replacement of the myocardium with genetically normal tissue (9) . However, the molecular mechanisms responsible for improvement in myocardial performance were not considered in detail in these studies.
In this issue of Critical Care Medicine, Sun et al (10) sought to determine whether intramuscular implantation of bone marrow-derived mononuclear cells (BMDMCs) would result in a sustained improvement in cardiac performance and suppression of putative mechanisms of heart failure in a nonischemic model of DCM. The model of DCM was identical to that of Nagaya et al; however, the treatment protocol differed in that the stem cells were CD31ϩ, indicating an endothelial stem cell lineage. Nonetheless, the treatment resulted in significant and sustained (up to 90 days) improvement in left ventricular function, which was associated with reduced myocardial fibrosis, greater expression of connexin43, and a reduction in left ventricular volume. In keeping with the study of Nagaya et al showing differentiation of stem cells into vascular components, there was a significant increase in the number of blood vessels and only a fraction of the stem cells were shown to express cardiomyocyte-specific proteins. It is unclear if some of the stem cells actually differentiated into vascular structures. The study was designed to measure multiple variables that are believed to contribute to the development of CMP, including oxidative stress, expression of transcription factors regulating energy metabolism, programmed cell death (apoptosis), and the expression of immune mediators (e.g., matrix metallo-proteinase9, interleukin-10). Compared with the untreated DCM group and the negative control group treated with BMDMCs alone, the DCM group treated with BMDMC showed a statistically significant normalization of all measured parameters. Thus, the data strongly support the conclusion that intramyocardial injection of BMDMCs ameliorates the molecular and biological processes that contribute to the development of autoimmune DCM.
Although these results confirm the findings of previous studies showing benefit of stem cell implantation in the con-text of DCM (4 -6) and provide some new insight into the protective mechanisms, a number of important questions remain unanswered. For instance, not all stem cells are equal. Endothelial progenitor cells have the capacity to promote neovascularization more effectively than do mesenchymal progenitor cells (11) . In this context, administration of endothelial precursor cells in the setting of ischemic CMP are shown to be superior to mesenchymal progenitor cells in terms of infarct regeneration and recovery of cardiac function (12) , which may partially explain the negative results of the Myoblast Autologous Grafting in Ischemic Cardiomyopathy trial (8) . Because the pathogenesis of DCM differs from ischemic CMP, the benefits of specific stem cell treatments in the setting of ischemic CMP may not apply to DCM. Thus, it is worthwhile to consider which progenitor stem cell type is preferred for the treatment of DCM.
The results of experiments conducted in the rat models of cardiomyopathy may not readily apply to human disease. Important differences existing between humans and rodents include different myosin heavy chain isoforms, much faster heart rate in rodents, distinct myocardial function and gene regulation, and different responses to pharmacologic treatments (13, 14) . Larger animal models may be more relevant to humans; however, ethical concerns, the costs attendant to conducting large animal research, and the inability to manipulate gene expression limit their use. Another important variable is the inability to closely model the clinical progression of human disease in rodents, which could influence the results of stem cell treatment. In this study, BMDMC treatment was administered 35 days after the induction of conditions that ultimately lead to DCM. However, significant left ventricular dilation was not present at the time of BMDMC treatment (10) . By contrast, all human trials have been conducted on patients with advanced and long-standing disease. Thus, it is unknown if stem cell treatments are most effective in early or late stages of disease. Given these differences in the timing of treatment relative to disease onset, and fundamental differences between species, it is prudent to recognize the significant challenges confronting investigators as they attempt to translate the results of rodent models to human disease.
The source of stem cells for human applications has become an area of intense investigation and interest. In addition to avoiding ethical conflict, the major advantages of treatment with autologous stems cells, such as those derived from the bone marrow or blood, compared with stem cells derived from fetal tissue, is the avoidance of rejection and reduced risk of malignant transformation of the stem cells. However, BMDMC treatments involve large volume bone marrow harvests and a decrement in stem cell functionality has been observed in patients with multiple comorbitities associated with cardiovascular disease. Umbilical cord blood can serve as an alternative source of hematopoietic-derived endothelial precursor cells and have demonstrated vasculogenic potency in animal models (15) . Finally, autologous skeletal myoblasts tend to provoke arrhythmias, are large enough to cause embolic complications when administered by intravascular injection, and may lead to distortion of cardiac architecture (15) . Although it is clear that stem cell transplants hold great promise for the treatment of the heart and other vital organ failures, much work remains to be done to refine these techniques. Vincent I n this issue of Critical Care Medicine, Manthous presents a novel meta-ethical analysis of shortening the dying process (SDP). She concludes that society's aversion to the practice is based on moral intuitions rather than reason, thus prohibition of SDP potentially constrains the liberty of a minority of patients (1, 2) .
Manthous references the ETHICUS study (3) , suggesting that some physicians blur the fine line between intent to palliate and intent to hasten death. Findings of the ETHICUS study seem to imply that because some physicians intend to kill their patients through SDP anyway, and because this intent cannot always be accurately discerned, perhaps SDP ought to be licit rather than ger-rymandering with the abstruse principle of double effect (4) . Although it may be true that intent is sometimes obfuscated, it is unwise to conclude that the distinction between directly killing a patient and allowing a patient to die of their underlying disease is moot because of a few Machiavellian providers.
Manthous appears to argue that our aversion to SDP is fundamentally irrational and that we might be inclined to reevaluate and ultimately accept the practice if more encouraging terms, such as "physician-assisted death for irreversible suffering," were used. Language plays a crucial role in perception. However, we question whether employing a euphemism to "rationally" consider the issue is appropriate or if it simply creates the precise problem the author wishes to avoid.
In other words, is it acceptable to make something that is inherently unpalatable palatable through creative linguistics? Moreover, even if our aversion to SDP is based on moral intuitions or some type of innate neural hard wiring, it does not follow that such repugnance is necessarily irrational. That is, simply because we may be predisposed to assumptions does not mean that we are unable to challenge them.
Thus, although we may sometimes make judgments before taking the time to reason and reflect before taking the time to reason and reflect (e.g., physician-assisted death is prima facie immoral), this does not necessarily mean: (1) that such intuitions ought to be regarded as meaningless, (2) that we are intellectually paralyzed to evaluate those intuitions, or (3) that such moral intuitions do not persist for an important reason (namely, with regard to the judgment about physician-assisted death, that we are better off avoiding killing others all things being equal).
The author acknowledges that regulations regarding SDP must be judiciously employed, although she does not explain why such safeguards are necessary. In our estimation, this discussion cannot be divorced from metaethical analysis if we wish to move from theory to practice.
Society has clearly entered into a normative debate concerning SDP (5, 6) . The persistent argument that effective pallia-tive care may not always be available thus necessitating physician-assisted death is contentious (7) . Palliative care has continued to improve and is available for all patients, barring the most unlikely circumstances.
Further, if physicians were allowed legal authority to palliate by benevolent execution, this authority would not necessarily be specialty specific. A critical care physician with years of training and experience in effectively treating a dying patient with multiple organ failure would assuredly be an expert in the how, why, and wherefore of euthanizing patients. However, many other practitioners with the same MD degree have no training or experience in this area, and euthanasia by their hand might take on a radically different complexion. There would be no kind of quality assurance for the procedure if undertaken by these physicians.
Physicians have traditionally enjoyed trust in their position as healers or, in the absence of healing potential, at least palliators (10) . This trust is predicated on the premise that physi-cians have 100% incentive to benefit patients and 0% incentive to harm them. Should physicians take on the mantle of benevolent executioner, this clear delineation would be blurred, affecting public trust, especially in the context of organ donorship.
Debating the rationale for our moral judgments is intellectually intriguing and a worthwhile pursuit. Ultimately, however, we find no difficulty in accepting that aversion to SDP is ingrained in our genetic and cultural makeup for meaningful reasons. Perhaps the author fears that society has blindly justified its reasons to fit such intuitions, but the rigorous and ongoing societal debate does not support this contention. ade Challenges, duty hours, and metrics in the intensive care unit resident rotation* M ost practicing intensivists experienced very different intensive care unit (ICU) rotations during their training than the current generation of residents and fellows. Constant evolution of critical care science, duty hour restrictions, and good evidence that extended work hours contribute to ICU errors (1) are the major factors that have driven changes in the structure of resident ICU training. Although a few exceptions exist (see Ref.
2), many ICU rotation changes have not been accompanied by rigorous and well-designed studies to examine the intended and unintended impact of these changes on critical care education.
One source of uncertainty in the design of residency rotations is the amount of time that general residents should spend in the ICU. There may be no definitive answer to the question of "what is the ideal number of duty hours or months spent in the ICU?" However, in this issue of Critical Care Medicine, Mullon et al (3) have made an important attempt to improve our understanding of "The impact of adding one month of ICU training in a Categorical Internal Medicine Residency Program." Unexpectedly, the main results of their analysis were "no significant or sustained benefit in the observed cognitive or clinical skills of the residents who received one additional month of ICU training." Although disappointing, these results are of great significance within the larger context of ICU resident education. These results should provoke a broad discussion on the design and implementation of resident training curricula in the ICU.
Mullon et al based their study design and analysis on the addition of an additional 1 month of ICU training for postgraduate year 2 residents in a single internal medicine residency training at the Mayo Medical Center. The authors compared resident performances and self-assessments from the cohort who had 2 months of ICU rotations with those who had 3 months. The initial rationale for the addition of the mandatory rotation was stated only as a perceived need. The authors did not describe new specific resident education goals or deficiencies with the existing training program to further explain this new rotation. It is unfortunate that the rationale for such a significant change was not more precisely defined or described.
For the primary outcome measure of resident self-assessment scores on the performance of critical care procedures and management of septic shock, there were no sustained, significant differences between the residents who rotated for 2 or 3 months. Similarly, for the other primary outcomes including compliance with management protocols for septic shock, procedure completion, end-of-rotation multiple choice exams, and attending evaluations, the effect of the additional 1-month ICU rotation was insignificant. These results are consistent with a prior study of residents during a surgical ICU rotation that demonstrated no improvement in examination results after 7 weeks of ICU experience (4) .
This study has important strengths including careful attention to comparison of resident characteristics, inclusion of a large number of residents, and careful collection of data in three different domains including resident selfevaluations, procedural skills, and measures of specific patient care processes. Limitations of the study include the relatively narrow focus on the assessment metrics and the use of standard order sets for sepsis management. These factors may have minimized differences between the resident groups. The chosen metrics were insensitive to differences in many other important domains of learning and competency. The self-assessment survey instrument used questions and answer choices, which were ambiguous or imprecise (e.g., few intensivists would preferentially choose the answer "Able to intubate Mallampati Class IV" without further clarification). Additional sources of confounding may have included the constant bedside presence of ICU fellows or attendings who may have prevented significant variation in the performance of procedures or other aspects of bedside care. The attending physician observed the residents for only 1 week of the rotation, which may have limited the sensitivity of their observations to detect and report small differences in resident performance. Ultimately, given the single-center, observational design, it would be difficult to generalize these results and apply them to other internal medicine residency programs, other subspecialty residents, or fellows.
Although it is possible to attribute the main results of this study to design limitations, the more difficult task is to consider the possibility that these results are true. Since 2003, when resident duty hour limitations were widely implemented, the educational environment and hence resident learning has significantly changed. Faculty surveyed about the impact of duty hour restrictions report an increase in clinical workload, a decrease in time spent teaching, and decreased quality of teaching (5) (6) (7) . From the residents' perspective, workload intensity gauged by numbers of admissions per call night and total numbers of patients covered are directly related to loss of sleep and lower likelihood of participation in educational activities (8) . Thus, it is by no means guaranteed that additional rotations in the ICU will lead to improved competency if the educational environment has deteriorated.
There is no question that ICU rotations can provide a rich and diverse learning environment for medical students and residents in all subspecialties. However, a 1-month ICU rotation may be of little benefit unless precise goals and objectives for that rotation are defined, measured, monitored, and constantly improved. In our current era of duty hour limitations, time-pressed faculty, and high-intensity workloads, it is no longer adequate for intensivists to assume that an ICU rotation will consistently benefit all learners. Furthermore, traditional assessment metrics including postrotation multiple choice exams and brief faculty evaluations are not likely to reflect the true breadth and range of learning experience the ICU offers.
At a minimum, the process of care for our critically ill patients will constantly change as new research findings are applied at the bedside. In this changing environment, intensivists must engage residency program directors, clerkship directors, and accreditation agencies in a dialogue to define a critical care educational agenda. These discussions should identify the expected benefits of ICU rotations and lead to the development of measures of these outcomes. The specific educational objectives that demonstrate why the ICU rotation is an essential component of medical school or general resi-dency need to be defined and clarified. Once this has been accomplished, duty hours and months of required rotation can be determined from longitudinal assessments of the skills and competencies defined by the educational objectives of the critical care rotation.
Academic intensivists and residency program directors are redefining and measuring the knowledge, skills, and competencies that are best learned in the ICU. Core learning based on general medical knowledge and the relatively constant concepts of medical ethics and pathophysiology can be balanced with the most recent progress in management of critically ill patients. The traditional emphasis of the ICU rotation on pathophysiology, management of organ failure, and resuscitation can be expanded and viewed within the Accreditation Council for Graduate Medical Education competency framework to permit consistent and broad-based assessments of competency (9) . The immediately visible outcomes of decision making combined with the shared responsibility of multidisciplinary care make the ICU environment ideally suited for learning quality improvement, communication skills, teamwork, and systems-based care.
Besides the ICU, there are few other learning environments that can provide a truly broad-based and comprehensive medical learning experience. Residents who rotate in ICUs have the opportunity to make critical observations, carry out interventions, and immediately observe the effects of their assessments and interventions. Since Osler's time, this process of observation then intervention then repeat observation has been the cornerstone of medical education and medical decision making. Although Mullon et al did not measure a significant difference between 2 and 3 months of ICU rotation, these results are likely to reflect the limited scope and range of their metrics rather than a limit of the learning opportunities in the ICU. These results represent a challenge to any assumptions that more ICU rotation time will be beneficial to residents. Critically associating* I t has long been recognized by clinicians in the intensive care unit that despite exposure to the same infectious/inflammatory insult, the response across populations is broad and varied with respect to susceptibility, morbidity, mortality, and response to therapies. Genetic variation as a basis for this disparity is now a focus of sepsis research with hopes that it will provide a tool to identify susceptible patients, target more specific treatment to individuals, and improve the overall outcome of sepsis (1, 2) . The overall concept of genetics influencing the course of infection is well founded given the landmark study of Sorenson et al (3) indicating that premature death from infection has a stronger heritable component than premature death from cardiovascular disease or cancer.
Single-nucleotide polymorphisms are single-base changes in DNA and are the most common type of genetic variation in the human genome, with more than 10 million single-nucleotide polymorphisms mapped and deposited in public and private databases. Gene-association studies examining various single-nucleotide polymorphisms of genes potentially playing a role in sepsis are becoming increasingly prominent in the literature. Examples include a toll-like receptor-2 polymorphism predisposing to life-threatening bacterial infection (4), toll-like receptor-4 polymorphisms affecting susceptibility to Gram-negative sepsis (5) and higher frequency of septic shock (6), a tumor necrosis factor (TNF) polymorphism that increases the risk for severe sepsis after trauma (7) , and polymorphisms associated with increased risk of severe sepsis after burn injury (8) .
Another example of a gene association study, focused on single-nucleotide polymorphisms and sepsis, appears in this issue of Critical Care Medicine (9) . This is a case-controlled, candidate gene association study examining the association between the TNF (Ϫ308) polymorphism, and susceptibility to, or death from meningococcal sepsis. Read et al conclude that patients homozygous for this TNF polymorphism may be more susceptible to developing meningococcal disease, but are not at greater risk of dying once they develop meningococcal disease. Importantly, this association was compared with eight other polymorphisms that are in strong linkage disequilibrium with the TNF (Ϫ308) polymorphism, with corrections for multiple comparisons.
Anticipating that gene association studies will continue to proliferate in the field of critical care medicine, the article by Read et al provides an opportunity to review published, stringent, editorial criteria for evaluating the quality of gene association studies. As stated in an editorial published in Nature Genetics, the ideal gene association study should have a large sample size and small p values, report associations having biological plausibility, and the allele should affect the gene product in a physiologically meaningful way (10) . In addition, the editorial puts forth another set of very high standards stating that the ideal study should include an initial study and an independent replication, and that the gene association should be observed in the context of both family-based and population-based control cohorts. Other published criteria emphasize the importance of having clearly defined cases representing a spectrum of disease severity, of matching cases and controls for environmental risk factors and ethnicity, of presenting and statistically analyzing potential confounders, of reporting equilibrium of the allele(s) of interest, and of power calculations targeted toward detection of positive associations (11, 12) .
Meeting all of the above criteria is extremely challenging and one would be hard-pressed to find a published gene association study that unquestionably and entirely meets this level of stringency. Thus, the following is not intended as a statement of quality regarding the article by Read et al. Rather, we will examine the article in the context of the above criteria to illustrate the challenges inherent to conducting rigorous gene association studies in critically ill populations.
The study by Read et al has biological plausibility given the well-known central role of TNF as a modulator of the innate immune system. The cases are clearly defined by way of reference laboratory-based confirmation of meningococcal disease. The study takes into account potentially confounding factors, including other biologically plausible genes that are in linkage disequilibrium with the TNF polymorphism, and conducts statistical corrections to evaluate the influence of these confounding factors. Finally, cases are well documented with respect to age, ethnicity, serogroup, and clinical outcome.
The number of cases in the study by Read et al, Ͼ1000 cases, is impressive by any standard. Mira et al (13) previously demonstrated that the same TNF polymorphism was associated with a greater mortality rate in a general population of patients with septic shock and was based on 89 cases. Thus, assuming that the study by Mira et al provides evidence of a strong "gene effect," the study by Read et al would seem to be sufficiently powered to detect an association with mortality. Alternatively, the "gene effect" in a more homogeneous group of septic shock patients (i.e., patients exclusively with meningococcal disease) may be smaller and therefore would require a greater number of patients to detect a significant association.
As stated earlier, in the ideal gene association study the allele of interest should have a physiologically important effect on the gene product. To this end, Read et al provide ex vivo stimulation experiments indicating that the TNF polymorphism is associated with increased TNF production in response to N. meningitidis or meningococcal-derived lipopolysaccharide. However, exactly how increased TNF production would confer increased susceptibility to meningococcal disease is a matter of debate.
Finally, the study by Read et al used anonymous samples from a pool of blood donors for the control cohort (a population-based control cohort). This control co-hort is appropriate with regard to size and geographic relevance. It is less ideal with regard to known colonization with N. meningitidis. A more ideal control cohort would consist of subjects having known colonization with or exposure to N. meningitidis. We agree with the authors that deriving this type of cohort is a formidable challenge. It is not, however, impossible to derive such a control cohort, and the effort that would be required to generate this ideal cohort provides a strong example of how challenging it can be to conduct highly rigorous gene association studies in the context of critical illness.
Gene association studies should be conducted in the critically ill population. The heterogeneous clinical responses and presentations that we observe daily at the bedside provide all of the necessary general rationale that genetic polymorphisms have an important impact on our patients. Although conducting these studies in the context of critical illness is particularly challenging, we must nonetheless seek to conduct these studies with as much rigor as that of our colleagues in other fields. One potential solution to meeting this challenge is the development of multi-institutional and multinational research consortia specifically dedicated to gene association studies.
Erika Stalets, MD Hector R. Wong, MD Division of Critical Care Medicine Cincinnati Children's Hospital Medical Center Cincinnati, OH Planes, trains, and the intensive care unit: The impact of stress on the multidisciplinary team* I n this issue of Critical Care Medicine, Piquette et al (1) report a study of health caregivers' perceptions of factors that lead to stress in the intensive care unit (ICU) and the associated impact on team performance. A one-time semistructured interview was conducted among volunteer nurses, attending physicians, residents, and respiratory therapists to identify categories of common ICU stressors. The conceptualization of stress by Lazarus and Folkman was used as a framework for analysis of the results. Stressors were divided into nonthreatening (emergencies and critical unstable patients perceived as challenging) vs. threatening (situations with lack of knowledge, apathy, and incompetent staff) crises. The stressors identified in nonthreatening crises included high work demands and heightened awareness in striving for patient survival. Encouragingly, the study reports that participants believed team member contributions could help solve the crisis. Additionally, perceiving a sense of control deemed many of the events challenging rather than stressful. The authors propose that in nonthreatening crises, a little stress maybe good. Small amounts of stress may be perceived as a challenge tending to energize and satisfy the ICU team member. When the challenge has transformed into exhaustion due to demands that cannot be met, feelings of stress develop, positioning us for illness, injury, and job failure (2) . So, a little stress is good, too much is bad.
The authors found that when ICU team members were uncertain as to their ability to resolve a threatening crisis, symptoms of stress and distress were induced (1) . Distress presented most often when there was a lack of information or when unpredictable changes occurred in situations of worsening patient condition. In this situation of higher demands, team members may be perceived as "unhelpful bodies," contrasting significantly with self-perception in a nonthreatening crisis. Disagreement between consultants and the primary team and lack of experience and coordination among staff were recognized themes in threatening crises. Witnessing the distress of others, especially if a strong emotional response was displayed, often interfered with the ability to execute one's assignment with team dysfunction escalating to an irresolvable level. The overwhelming feeling of anxiety among the team further impaired the interprofessional teamwork and threatened patient outcome.
Factors that lead to stress during a crisis are not infrequent in most ICUs. Situations arise that are out of the ICU team's control and bad outcomes cannot be avoided. The unpredictable course of ICU care is similar to the ever present potential for crisis in the airline or railroad industry. Crisis is capable of evoking physical, mental, and emotional responses that may impact performance (3) (4) (5) in the airline cockpit, lead train, or ICU. In a study of train drivers, emotional stress increased during a change in speed as in starting and stopping (4) . A study comparing airline cockpit crew to ICU staff found that medical staff, unlike pilots, denied the effect of stress and fatigue on performance and reported barriers in the ability to discuss errors (5) .
It may seem that stress management is a good solution. However, stress management focuses primarily on the individual and may focus blame on individual members of the team. This seemed to be a common theme in this study with high emotional responses in threatening crises. ICU conflicts and stressful working environments were independent predictors of severe burnout syndrome in both intensivists and nurses leading to high turnover (6, 7) . Reducing conflict and improving communication is likely the remedy to decreasing ICU stress (8) . A physician once told me that one should not have stress if he or she has the ability to handle conflict and the understanding that conflict is driven by a personal difference in ideas or principles. Evaluating perceptual differences in collaboration and communication with the team can help facilitate effective working environments, improve teamwork, and contribute to high-quality care (9) . Team acknowledgment of stressful conditions and the mutually agreed upon response is essential to facilitate the development and implementation of more effective coping mechanisms.
Crisis Resource Management, as the authors have pointed out, is another potential solution. Critical Incident Stress Debriefing is a tool used in the railroad industry to mitigate problems caused by exposure to traumatic incidents (10) . A similar strategy would likely be effective in the ICU. Debriefing after a code, death of a patient, or crisis situation may assist staff with improved well-being and potentially decrease stress and errors in a future crisis.
An additional solution may be as simple as improving daily communication. The multidisciplinary team approach to achieve daily consensus provides better communication, education, coordinated care, and feedback (11, 12) . A daily goal sheet is useful in achieving this goal (6, 12, 13) . Improvement in communication has been associated with improving job satisfaction, facilitating problem solving, and lowering personal stress while decreasing isolation and feelings of conflict (6, 14) .
Even the most careful plan to alleviate ICU work-related stress will not eliminate it completely. Efforts to manage stress with organizational change and stress management can improve working conditions. However, there are limitations in this study including the use of singlecenter data and the use of one internal clinical fellow to conduct the interviews, as opposed to multiple observers with blinded assessments to verify the absence of interobserver bias. Nevertheless, similar findings may be easily identifiable in many institutions. A third limitation of this study is that there was no direct observation of real ICU medical crises to support their results. It is possible that the perceptions of the staff and that of an unbiased observer may differ. Although not as good as real-time assessment, an alternative method to address this limitation is the use of a simulation lab (15, 16) . This is done with the creation of a simulated crisis situation, including a representative from each member of the multidisciplinary team, as well as an observer to more objectively capture errors and associated coping methods predicted to occur in a real ICU medical crisis.
A more effective way to decrease ICU stress is organizational change, which includes a defined purpose, organizational and individual goals, and organizational support leading to a holistic team-based approach. Whether in the airline, rail, or medical industry, communication is the key to a successful functioning team. Including an annual course in communication skills, conflict resolution and dealing with difficult people and situations may be helpful for staff. Breaking down the barriers to improving ICU culture may decrease conflict and facilitate teamwork, decreasing demand and stress. Intensive care is reliant on the enduring integrity of the team with each member possessing a collective responsibility to contribute to the smooth functioning of the ICU (11 (4) . Other studies evaluated QoL based on specific pa-tients' characteristics (e.g., in the elderly patients) (5) .
QoL is an important outcome measure in clinical studies. However, the interpretation of QoL studies is limited by several factors including incomplete data collection and the limited reliability of responders' answers. Other relevant but unresolved issues for assessing the effect of critical care illness on QoL include relying on reports from the "significant other" as well as inability to assess with certainty the different aspects of QoL before illness onset.
Examining long-term outcomes such as the QoL of subjects who survive severe sepsis constitutes a very important assessment measure from the epidemiologic and economic standpoints. The oc-currence of sepsis is increasing with an estimated annualized increase in incidence of 8.7% (6) . At least 750,000 subjects are diagnosed and treated for severe sepsis each year in the United States of whom 20% to 30% succumb to their illness (6) . The yearly cost associated with caring for all-cause septic patients approaches 17 billion dollars in direct healthcare expenditures (6) . Thus, sepsis represents a substantial healthcare burden in the United States and throughout the world.
In this issue of Critical Care Medicine, Karlsson et al (7) evaluated the QoL in sepsis survivors discharged from intensive care units in Finland by reporting the quality-adjusted life years derived from the EuroQoL (EQ-5D). The EQ-5D measure, which consists of five-item descriptive system of health states and a visual analog scale, is the most frequently used instrument for calculating qualityadjusted life years (8) . In general, qualityadjusted life years are considered as an important measure of effectiveness of health care although the number of studies in which quality-adjusted life years was used to assess actual measurements of patients' health-related QoL is still fairly limited (9) . In this study, Karlsson et al provided a new look on QoL measures in severe sepsis survivors using the EQ-5D score. The authors' main findings were a lower but reasonable and costeffective QoL for patients surviving sepsis. Interestingly, the mortality in the 2 years after hospital discharge was considerable, 35% in those older than 55 years, which further emphasizes the significant toll imposed by this illness even after surviving the acute event. Their findings certainly help to justify the high resource utilization and costs of aggressively supporting this population of patients.
Although this study provides important insights regarding long-term outcomes in sepsis survivors, several limitations are worth mentioning. Proxies are a frequent and necessary source of information about patient's status. The reliability and validity of collecting information from a surrogate such as a family member is a central issue, because subjects may not have the capability to complete these lengthy questionnaires during or even after critical illness. Although proxy reports may appear valid in many settings, they do differ from patients' reports (10) . The degree of agreement for QoL assessments between patients and their primary family caregivers has been best determined in patients with terminal malignancy. In patients with cancer, family caregivers agreed at least moderately well on the patients' QoL but, when discrepancies existed, family caregivers held a more negative view of patients' QoL than did patients (11) . The extent of agreement between patients and their respective proxies has not been established in sepsis survivors, and so the reliability of proxy responses cannot be guaranteed in this particular patient population.
For many studies, investigators would also like to know the baseline QoL of individuals before the critical illness. The validity of asking someone after a recent critical illness about the quality of their life before the critical illness has not been fully determined. Information concerning QoL before illness onset was unfortunately lacking in almost 80% of the subjects in this study. Another issue is incompleteness of data collection. This per se may be an indicator of distress after critical illness, although no significant difference in disease severity was noted in this study between respondents and nonrespondents. Furthermore, cultural differences in preferences for certain health states do exist and are dependent on the level and dimension of health considered. Regression model estimates indicated that Finnish and U.S. respondents have different preference valuations for different levels of health in the visual analog scale valuations of the EQ-5D measure (12) . Thus, extrapolation of this study results to the U.S. population cannot be made with certainty.
Each of these issues must be considered very carefully in any study designed to examine QoL outcomes after chronic or severe illness. To date, studies of specific interventions in sepsis survivors have not used QoL outcome measures. This represents an important area of future research to help establish potential tools designed to address the long-term consequences of critical care illness.
Tarek (1) hypothesized that fluid flux across the capillary membrane was governed by a balance between oncotic and hydrostatic forces and influenced by permeability, clinicians have been seeking resuscitative fluids with oncotic properties to prevent or minimize the formation of edema. Using Starling's model, benefits of colloids in the resuscitation of shock are likely to be more pronounced in nonpermeability than permeability shock because loss of colloid through permeable capillaries will reduce the retention of fluid in the intravascular space. There is considerable interest in the effects of colloids on edema formation in the lung because of the role of this organ in gas exchange and oxygen delivery.
Colloids have been popular fluids for resuscitation for all types of shock because of these theoretical benefits. Colloids that are commercially available today for patient use include 5% albumin, 4% gelatin (available in Europe), and 6% hydroxyethyl starch. Each of these colloids has oncotic properties that approximate those of human plasma. They have been studied in a large number of clinical trials of critically ill patients with and without permeability disorders and compared with conventional crystalloid fluids. The results of these studies have been conflicting and often controversial.
One of the problems with early studies comparing colloids and crystalloids is that experimental resuscitation protocols did not always mimic the approach used by the bedside clinician. Many studies compared arbitrary aliquots of colloid with larger aliquots of crystalloid because of the tendency of crystalloid to move from the circulating space to the interstitial space. There was difficulty in extrapolating these results to the bedside because clinicians rarely use a predetermined volume to resuscitate patients. In more recent times, comparative colloid/crystalloid studies have used protocols that resuscitate to physiologic end points. These end points, which may include blood pressure, urine output, central venous pressure, and/or pulmonary artery occlusion pressure reflect current approaches to the management of shock in critically ill patients.
The study reported in this issue of Critical Care Medicine by van der Heijden et al (2) attempts to compare colloid with crystalloid resuscitation using physiologic guides to fluid resuscitation. They compared the two types of resuscitative fluids in groups of patients with and without sepsis, a common permeability disorder. They examined the effects of fluid resuscitation on the lung. After resuscitation, they measured a pulmonary leak index with Gallium-67-labeled transferrin, extravascular lung water using a thermal dye dilution technique, and a lung injury score using a standardized chest radiograph interpretation method. They compared the crystalloid 0.9% NaCl (normal saline) with colloid groups (4% gelatin, 6% hydroxyethyl starch, and 5% albumin). Because there was insufficient statistical power for comparisons between the individual colloids, they compared the crystalloid group with the colloid groups combined. Fluids were given using central venous pressure as a guide according to a modification of an algorithm (3) that required active fluid resuscitation until signs that the limits of right heart compliance were reached (e.g., a central venous pressure increase Ͼ5 mm Hg after a 200-mL aliquot infusion).
The authors found no differences in extravascular lung water, pulmonary leak index, and lung injury score between the crystalloid and colloid groups. This negative result applied to both septic and nonseptic patients.
Of interest, however, is that authors did note a significant inverse correlation between colloid oncotic pressure (COP)-central venous pressure gradient and extravascular lung water for all patients after the 90-min period of fluid loading. The COP-central venous pressure gradient sums the opposing hydrostatic and oncotic forces of fluid in the microvascular space, and a high gradient favors intravascular fluid retention. A similar inverse correlation between COP-pulmonary artery wedge pressure gradients and radiographically determined pulmonary edema has been observed in an earlier study of critically ill patients (4). One must be concerned that variability within the colloid groups may have masked a positive result favoring increased lung water accumulation in the crystalloid group. Indeed, the three colloids are distinctly different from one another. Albumin is a small lancet-shaped protein, gelatin is characterized by long polypeptide chains, and hydroxylethyl starch is a highly branched molecule. The colloids also differ with respect to half-life, degradation in the circulation, and oncotic properties.
The authors also confirmed colloids to be potent volume expanders, a finding that has been observed in many studies. After 90 minutes of resuscitation, colloids produced greater increases in central venous pressure, cardiac index, and intrathoracic blood volume compared with crystalloids. The ability of colloids to rapidly restore circulating blood volume was upheld in this study and supports the practice of using these fluids in the early stages of resuscitation. The impact of colloids on lung water accumulation remains uncertain. Nevertheless, the significant correlation between COP-central venous pressure gradient and extravascular lung water in this study suggests that active interest in potentially beneficial effects of these fluids should be maintained.
Marilyn T. Haupt, MD, FCCM Pulmonary and Critical Care Geisinger Health System Danville, PA L ung transplantation improves the odds of survival for selected patients, but with a significant liability (1, 2) . In this issue of Critical Care Medicine (3), Song et al report that increased survival in lung transplant recipients is accompanied by exacerbations requiring frequent hospitalizations, higher levels of psychological stress than in other organ recipients, and a "low sense of mastery for managing their illness." The authors state that these patients and their families are "critical about continuity of care as their health condition deteriorates."
We are a culture of hope and of assurance that if we work hard enough and believe strongly enough, nothing is impossible. The majority of time, energy, and money in healthcare delivery is spent attempting to wrest the grim reaper from the hospital bed in the last days, hours, and minutes of life (4) . Many physicians are personally affronted by death and assure the patient and family that death will occur only after every conceivable maneuver has been performed to divert it (5) . Palliative care has sometimes been viewed as "giving up" and been contemplated only after the abandonment of all hope of a favorable outcome (6) . For these reasons, dis-cussion of comfort care has not been part of the "do everything" approach.
Pushing the envelope of clinical practice has unintended consequences. Aggressive healthcare delivery increases the likelihood of debilitating dependence on life support (7) . We admit patients for advanced life support not necessarily according to a rational probability of success but in the hope that technological devices geared toward reversal of organ failure will work miracles (8) . This policy increases the chance of diminishing returns and the potential for open-ended distress, and therefore forces us to consider what constitutes terminality.
Terminality means different things to different people at different times and can be divided into "hard terminality" and "soft terminality" (9) . Hard terminality describes a situation in which the patient will die even with the assets of critical care life support because of organ system failure. Hard terminality is a one-dimensional snapshot. It is the end. The term soft terminality is used in a multidimensional critical care environment when death will occur from organ system dysfunction but can be prolonged through continued support of dysfunction. Such support can create open-ended discomfort and distress. At some point, survivability becomes moot and the focus shifts to quality of life, about which it is possible to make choices.
Those choices frequently boil down to forgoing life support to end distress. Although there is no moral or legal difference between withholding and withdrawing treatment, families often have more difficulty with the latter. When a mori-bund patient has made his or her wishes known beforehand, the family generally finds limiting further aggressive intervention less traumatic because they recognize that further treatment would be unacceptable to the patient. Once lifesupporting care is instituted, however, thoughts about withdrawal bring to mind a different picture of the outcome, and the family may be less inclined to remove such therapies.
With the institution of life support, a family's decisions become inextricably linked to an outcome that is no longer inevitably fatal. The potential now exists to manipulate "life," a comfortable path of least resistance. Because there are now variables they can control, the family is more apt to view withdrawal of support as hastening death rather than as a means of avoiding prolongation of dying. The healthcare team should explain that withholding and withdrawal, when appropriate, are equally palliative.
Because many aggressive care plans exist, and patients and their families are invested in them, it must be made clear that treatment failure is a possibility. If failure occurs, the resultant distress must be managed as effectively as other portions of the care plan. Patients and their families should discuss palliative care before the need for it arises; discussion should not be put off until the last minute, when palliation must be instituted under the most trying conditions. Palliation should be an integrated part of health care, with all the potential variables understood and accepted before palliative care begins (10 Acute kidney injury by hydroxyethyl starch: Can the risks be mitigated?* I n three randomized trials with a total of 709 patients (1-3), hydroxyethyl starch (HES) significantly increased the incidence of acute renal failure (ARF), the need for renal replacement therapy (RRT), or both. These end points have not been evaluated in any other randomized trial evaluating HES. Based on the pooled results of these three trials, HES nearly doubled the odds of RRT ( Fig. 1 ). Extensive additional data from randomized trials, nonrandomized clinical studies, and case reports have also shown HES to be injurious to the kidney (4) .
A key question is whether the nephrotoxicity of HES can be mitigated. At least four approaches can be envisaged: 1) selection of HES solutions with lower molecular weight and substitution; 2) HES dose restriction; 3) reliance on HES solutions with lower concentrations and therefore lower colloid osmotic pres-sures; and 4) avoidance of HES in higherrisk patients. In this issue of Critical Care Medicine, Rioux et al (5) shed light on all the four approaches in a new retrospective study of 563 cardiac surgery patients. They examined the risk factors for postoperative acute kidney injury (AKI), defined as a 50% rise in serum creatinine within 4 days after surgery. HES infusion was shown to be a dose-related independent risk factor for AKI. Each additional mL/kg of HES increased the odds of AKI by 8%. Their study and other recent nonrandomized investigations evaluating ARF or RRT after HES exposure are summarized in Table 1 (5-10).
To minimize potential biases, Rioux et al applied multivariate statistical methods and propensity scores. Nevertheless, statistical adjustments cannot nullify the possible influence of unmeasured or unknown latent variables. On the other hand, retrospective studies enjoy important advantages in assessing safety. Such studies generally are relatively large and involve "real-world" patients rather than the lower-risk groups typical of randomized trials. Indeed, it was the retrospective studies that first signaled the increased risk of excessive postoperative bleeding in cardiac surgery patients receiving HES. This risk was confirmed by a meta-analysis of randomized trials (11) and prompted the US Food and Drug Administration to issue an additional warning against usage in cardiac surgery according to the Prescribing Information for HES of 450 kDa molecular weight and 0.7 substitution (HES 450/0.7) in saline vehicle. Clinical bleeding complications of HES were first reported 40 years ago (12) , and for nearly as long lower molecular weight and substitution have been proposed as a way to improve safety. Rioux et al infused pentastarch, a "modern" solution of lower molecular weight and substitution, usually designated as HES 200/0.5. Their data clearly show that "modern" HES solutions do not end the risk of AKI. Furthermore, in a systematic review of 92 studies, including 23 randomized clinical trials, there were no consistent differences in renal side effects related to HES molecular weight, substitution, or C2/C6 ratio (4) . Subsequent to the systematic review, further clinical studies have failed to detect differences in RRT requirement between HES 130/0.4 and HES 200/0.62 (9) , or in ARF incidence between HES 130/0.4 and older starches (10) . Furthermore, switching from albumin to HES 130/0.4 was associated with a marked increase in RRT (6) .
ARF has been reported after intraoperative administration of only 500 mL HES 70/0.5 (13) . It remains unknown whether a low enough HES dose may exist that would be free from nephrotoxicity. Rioux et al demonstrated increased risk of AKI at doses as low as 14 mL/kg, only half as great as the recommended maximum dose (28 mL/kg). In a study of 3147 intensive care patients, a median cumulative dose of 1000 mL admin-istered was associated with more frequent RRT (8) , as was the dose of Ͼ750 mL in 262 kidney transplant recipients (7) . These findings clearly indicate that adverse renal effects can occur at relatively low HES doses.
Rioux et al administered hyperoncotic 10% HES 200/0.5. A new nonrandomized study of 1013 intensive care unit patients suggested that hyperoncotic colloids might harm the kidney (10). However, colloid osmotic pressures were not measured in that study, and there was no accounting of concomitant crystalloid usage, therefore the actual oncotic forces in vivo were unknown. Thus, there is no sound basis to conclude that hyperoncotic colloids per se are nephrotoxic. Quite the contrary, in a recent metaanalysis of 25 randomized clinical trials with 1485 total patients, there was no evidence of renal injury due to hyperoncotic albumin (14) . Conversely, iso-oncotic HES solutions display the same deleterious renal effects as their hyperoncotic counterparts. In a randomized trial of 129 patients with severe sepsis or septic shock (2), iso-oncotic 6% HES 200/0.62 more than doubled the odds of ARF (odds ratio, 2.57; 95% confidence interval, 1.13-5.83).
Some patients may be at a higher risk than others for HES-induced complications. A recent systematic review recommended that HES be avoided completely in septic patients (15) . Such patients often require relatively large fluid volumes over an extended time period. It has been argued that in other settings such as perioperative fluid management the risks might be lower. Now, however, Rioux et al demonstrated that cardiac surgery patients also face heightened risk of renal dysfunction. Furthermore, in a large nonrandomized study of intensive care unit patients (8) , HES was in fact reserved for lower risk patients, as evidenced by a frequency of baseline RRT (2.2%) only half as great (p Ͻ 0.001) as that of other patients (4.4%). Nevertheless, subsequent RRT was more frequent among HES recipients (p ϭ 0.006).
All HES solutions, even at low dosages, seem to be inherently nephrotoxic. Epoetin alfa in the critically ill: What dose? Which route?* A nemia is common in critically ill patients and is associated with the use of blood transfusion for treatment (1) (2) (3) . The anemia associated with critical illness is similar to the anemia of chronic inflammatory disease (4 -6) . Inappropriately low endogenous erythropoietin production, in addition to blood loss, reduced red cell lifespan and iron availability, and impaired iron regulation, and inhibition of erythropoiesis by cytokines and the inflammatory response all contribute to the anemia of critical illness. The optimal treatment of anemia in euvolemic critically ill patients remains controversial.
There is consistent evidence, however, that a major feature of the anemia of critical illness is a failure of circulating erythropoietin concentrations to increase appropriately in response to reduced hemoglobin levels (7, 8) . These observations have suggested that treatment with pharmacologic doses of epoetin alfa might decrease exposure to allogeneic blood and raise the hemoglobin level in critically ill patients. But what dose and which route of administration for epoetin alfa in critical care?
A small randomized pilot study (n ϭ 160) demonstrated a reduction in red blood cell transfusion and a rise in hemoglobin with epoetin alfa treatment using a dose of 300 units/kg/day for 5 days and then every other day in anemic critically ill patients (9) . This was followed by a much larger randomized study (EPO-2, 1302 patients) using a significantly lower dose of epoetin alfa (40,000 units/wk), which confirmed the transfusion findings (10) . A third randomized study (EPO-3, 1460 patients) was performed using the weekly epoetin alfa dosing (40,000 units/wk) in which the primary outcome was again transfusion reduction (11) . No transfusion reduction was identified with epoetin alfa treatment in this third trial, although hemoglobin concentration did rise.
It is interesting to contemplate that these large clinical trials were performed without specific identification of the optimal dosing and route of epoetin alfa in critically ill patients. The dose and route of epoetin alfa used in EPO-2 and EPO-3 (fixed dose of 40,000 IU given subcutaneously once weekly) was extrapolated from clinical trials in non-intensive care unit patients and healthy volunteers (12, 13) .
Only one prior study (14) examined the pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa dosing in critically ill patients. They randomized 73 anemic critically ill adult patients (2:1) to epoetin alfa (40,000 units administered subcutaneously once weekly, n ϭ 48) or placebo (n ϭ 25) for up to 4 weeks in three Belgian intensive care units. All patients were to receive a minimum of 150 mg of elemental iron daily either orally or via nasogastric tube beginning on day 1 of the study. Parenteral iron was reserved for patients with documented iron deficiency (defined as transferrin saturation Ͻ20%). Although exposure to endogenous erythropoietin in the placebo group was only about 20% of the exposure to exogenous erythropoietin in the epoetin alfa group, mean change in hemoglobin level from baseline through day 29 was not different (1.9 g/dL and 1.6 g/dL in the epoetin alfa and placebo groups, respectively) but patients who received epoetin alfa had a higher reticulocyte response.
Although mean serum erythropoietin concentrations were approximately tenfold higher in the patients receiving epoetin alfa in this study, it did not result in a higher hemoglobin response. Was this related to inadequate exogenous erythropoietin administration, inadequate concomitant iron supplementation, or the inability of critically ill patients to respond to exogenous erythropoietin because of inflammatory response? In critically ill patients with severe anemia who refuse blood transfusion, it has been documented that much higher doses of both epoetin alfa and iron are required to increase erythropoiesis and hemoglobin (15, 16) .
In this issue of Critical Care Medicine, Arroliga et al (17) report the results of a prospective randomized open-label multicenter study in anemic (Hb Ͻ12 g/dL) adult intensive care unit patients (n ϭ 60) that determined pharmacokinetic and pharmacodynamic profiles of six different dosing regimens for epoetin alfa administered for a duration of 15 days. Only 30 patients (50% of the initial sample) were evaluable. Erythropoietin serum concentrations were 10 -45 times greater for intravenous compared with subcutaneous dosing. Mean absolute reticulocyte count peaked on day 11 or 15, and absolute reticulocyte count was greater for subcutaneous dosing, but the pharmacokinetics did not predict pharmacodynamic response in these anemic critically ill patients. This is an important study that further extends our knowledge regarding optimal dosing and route of administration of epoetin alfa for the treatment of anemia in critically ill patients. There are, however, some significant limitations to this trial that should be considered.
Use of iron supplementation was not required in the study protocol and was at the discretion of the investigator. Only 16 patients (27% of the study cohort) received at least one dose of supplemental iron. "Absolute" and "functional" iron deficiencies are the most important factors causing resistance to administered epoetin alfa. No data are available regarding testing for iron deficiency (i.e., zinc protoporphyrin or reticulocyte hemoglobin content) in these study patients. This is a potential explanation for no differences in absolute reticulocyte count despite significant differences in epoetin alfa dosing and higher serum erythropoietin concentrations in some of the study groups.
Maximal erythropoietic response may not be achieved with higher doses of epoetin alfa if relative iron deficiency occurs related to the use of erythropoietin without concomitant iron administration. There is evidence to support this from a prior randomized open trial. Critically ill anemic patients treated with epoetin alfa were found to have elevated zinc protoporphyrin concentrations indicating iron-deficient erythropoiesis, despite the concomitant use of intravenous iron saccharate (20 mg daily for 14 days) and epoetin alfa (300 IU/kg subcutaneously on days 1, 3, 5, 7, and 9) (18). Furthermore, it is well recognized that iron deficiency anemia and the anemia of inflammation may coexist in critical illness (19) .
Did older age and/or increased body weight contribute to altered pharmacokinetics and pharmacodynamics in this study? The study population had a mean age ranging from 45 to 60 years and groups B and F had higher mean age (60.8 and 61.1 years) compared with all other experimental groups (44.8, 49.6, 47.6 years). A recent population pharmacokinetic meta-analysis of recombinant human erythropoietin in healthy subjects (n ϭ 533) documented that the bioavailability of subcutaneous rHuEpo increased from 30% at low doses to 71% at the highest doses and was described using a hyperbolic model. The most important covariate effects were a decrease in the first-order absorption rate constant with increasing age, an increase in subcutaneous bioavailability with increasing baseline hemoglobin, and a decrease in bioavailability with increasing body weight (20) . Is this true in critically ill patients as well? The sample size in this study was too small to examine a wide range of ages, body weights, and initial hemoglobin concentrations. Additional concerns regarding subcutaneous absorption of drugs in critically ill patients with anasarca, cutaneous edema, and vasopressor use are well recognized.
So what are we to conclude from these data? First, intravenous administration of epoetin alfa did not elicit a more robust reticulocyte response than the subcutaneous route, but the degree of edema or vasopressor use present in these patients was not captured. Second, more frequent administration of lower doses of epoetin alfa was not superior to less-frequent administration of larger doses, but the total cumulative doses of epoetin alfa were similar in all groups (120,000 IU to 170,000 IU, Table 1 ).
The optimal dosing regimen and route of administration of epoetin alfa in critically ill patients for the treatment of anemia are yet to be determined. Additional prospective clinical trials with larger sample size are warranted to further investigate population pharmacokinetic and pharmacodynamic parameters of erythropoiesisstimulating agents, which should also incorporate alterations in iron metabolism associated with critical illness and inflammation and other patient characteristics. This issue gains greater importance as we recognize that epoetin alfa may have beneficial effects beyond erythropoiesis, including modulation of apoptosis and inflammatory response and intensive care unit outcomes (21 Making a difference to that one, one (documented) patient at a time*
A man is walking the beach after a storm, and comes upon a boy, who is throwing starfish washed up on the shore back in to the ocean. The man tells the boy: "Why bother, it won't make any difference, there are too many starfish." The boy, throwing another starfish back to the safety of the water, answers: "It makes a difference to than one." C ancer is an unfortunately common affliction of children. Pediatric intensivists encounter these children with respiratory failure due to complications of both the primary disease and its treatment. Two decades ago, poor outcomes observed in children with cancer and respiratory failure led to a pessimistic outlook for those patients who required intensive care (1) . Some authors then argued that extracorporeal membrane oxygenation (ECMO) should not be an option for critically ill children with malignancy or immunodeficiency (2, 3) . Advances in both oncologic and critical care medicine now offer children with malignancy and respiratory failure improved chances for survival with critical care management, including mechanical ventilation (4).
Although anecdotal, it is fair to assert that a decision to use extracorporeal life support (ECLS) in the care of children with cancer, when conventional management is inadequate to sustain life, is in the least difficult and certainly controversial. In this issue of Critical Care Medicine, Gow et al (5) report the largest series, to date, of children with the coexistence of malignancy and respiratory failure treated with ECMO.
This article is noteworthy for several reasons. The data are important for intensive care specialists, hematologists, and our mutual patients and families because we make difficult decisions about life support. The results are encouraging, and hopefully will inspire further efforts to improve critical care for these children.
Second, this article emphasizes the value of clinical research, even if done only one patient at a time. The article reports data from the Extracorporeal Life Support Organization (ELSO) registry (6), a data collection consortium originally conceived and inspired by Dr. Robert Bartlett. Early in the evolution of the use of ECLS for respiratory failure from bench to bedside, this registry was established to document the details of results of this then emerging therapy. This type of re-port then, is clinical research, collected one (documented) patient at a time.
More than 120 centers participate in this registry. These data consortiums foster and promote analysis of data, debate over technique, summation of complications, and importantly, comparisons to other interventions. The article by Gow et al underscores both the value of such databases, and also serves to demonstrate limitations and room for improvement.
Third, critical care is a team sport. The accomplishments documented in this article are the result of collegial and collaborative work performed by intensivists, in collaboration with colleagues from both oncology and surgery. The medical team is a partner in care with patients and parents because difficult options for treatment are deliberated.
Fourth, we might take this opportunity to consider how "criteria" for intensive care therapies evolve, are disseminated and modified, especially as we endeavor to care for ever more medically complex patients, with equally complicated interventions (7) .
Gow et al review the ELSO registry data for 107 children younger than 21 years with both hematogenous (73 patients) and solid tumor malignancy (34 patients). Forty-five of 107 (42%) patients survived ECMO. Eight patients subsequently expired in hospital leading to an overall survival to discharge rate of 35%.
It might be intuitive, although not evidence based, for an ECLS center to refuse extracorporeal support for a patient, based on unique, parochial, concepts of potential contraindications. It is notable that potentially serious complications of using ECLS in this population, bleeding and infection, were not significant in this report. In this series, survival was worse in patients with lower initial oxygenation as reflected in a higher oxygenation index. Mortality was also higher in patients with solid tumors and those who developed either cardiac or renal failure.
ECLS centers were surveyed for attitudes regarding the deployment of ECMO for children with both cancer and respiratory failure. Of responding centers, 95% would "consider" the use of ECLS therapy in these patients. The study is limited by the retrospective nature of the registry. Data were not available to accurately determine illness severity, therapy for malignancy, neutropenia, or risk of mortality. The absence of such important data suggests potential improvement in the ELSO registry data collection system.
The results of Gow et al are additive to the data of Gupta et al (8) who observed relative success in the use of ECLS in children with immunodeficiency (with the notable exception of children after bone marrow transplant). In that 2008 review of the ELSO registry, experience with children with ICD-9 codes or Current Procedural Terminology coding associated with immune compromise, a 31% survival rate was reported.
How then did criteria for the use of ECLS come to be? Can we, as a critical care community, learn any lessons from the history of the introduction of ECLS into critical care management of respiratory failure in children? How does experience modify such concepts as eligibility and contraindications for novel therapies, such as ECLS, in the care of critically ill children? We all would hope that welldesigned randomized trials could provide reliable data. Attempted randomized trials of ECLS in children, however, have not been successful, due to, among several reasons, size of trial, design flaws, and definitions of outcome. However, as pointed out by Dalton (9) this has not stopped the critical care community from using the therapy when "all else fails," in the care of the child with respiratory failure. The use of ECMO in neonatal respiratory failure was arguably a standard of care in many centers in the late 1980s (10) .
However, the evolution of the use of ECLS for children in respiratory failure required and/or inspired substantial effort in first describing the natural history of respiratory failure in children, defining the nature of "conventional management" for comparison, and arriving at universal definitions of disease severity and outcome (2, 11, 12) .
Documents and precepts, such as "Criteria for Extracorporeal Life Support," are often conceived by early investigators, evolve with experience, are tested and improved by the scientific community at large-one patient at a time. The use of the ELSO registry over the years, despite its faults, teaches that reported experience, collected one (documented) patient at a time, encourages progress.
Early in the history of the dissemination of ECLS technology, courses incorporating didactic material with laboratory experience were offered to help centers begin and improve ECLS teams. Early handbooks and lecture material published "criteria" for the use of ECLS in critically ill children. These were more or less based on what might be called "eminence-based medicine" (including, in the interest of disclosure, this writer's "opinion") (13, 14) .
Contraindications to ECLS were subsequently refined by collected, anecdotal experience, and modified by data, often reported in small case reports at the scientific symposia sponsored by the ELSO. For example, it seemed reasonable to assume that patients with postoperative congenital heart surgery would hemorrhage if placed on ECLS with its attendant heparinization. Experience proved this early skepticism wrong and bleeding can be controlled in the postoperative patient while on ECLS (15) . Early on, it was assumed that pulmonary hemorrhage was a "reasonable contraindication." Yet, ECMO has now successfully been used in patients with acute pulmonary hemorrhage from Goodpasture's syndrome and Wegener's granulomatosis (16) . Although it was intuitive to assume that bleeding, secondary to ECLS, would be a barrier to surgery, extracorporeal management is a mainstay of the pre-and postoperative care of the infant with congenital diaphragmatic hernia (17) . Experience, one (documented) patient at a time, has changed our approach to these patients.
To date, ECMO has been described in 3693 children with respiratory failure by 120 centers, with ECLS survival of 64% and survival to discharge of 54%. Debate continues concerning efficacy, cost benefit, and patient eligibility. Similar debates must accompany other emerging therapies and interventions, and extension of the use of extracorporeal support, to children with ever more complex diseases (6, 9) .
Gow et al have reminded us of the importance of clinical research. Once again, the ELSO registry serves as a tool to analyze result, and improve and criticize technique and data collection. one (documented) patient at a time. We are also reminded of the importance of teamwork in the critical care environment, for both patient care and analysis of results. Finally, such endeavors also remind us that we draw inspiration from our courageous patients and the uncommon resilience of their families.
What we do together makes a difference to this child, and to that one, and another, and another. . Joseph R. Pulse oximetry in critical care scoring systems* S everity scoring systems for critically ill patients can serve several important purposes. These include risk stratification for clinical trials, guidance for therapeutic strategies/protocols, outcome stratification for quality measures, and setting expectations with patients, families, and the care team.
The Sequential Organ Failure Assessment (SOFA) (1) score is one such scoring system that has been used for more than a decade in a variety of clinical and research settings. The SOFA score is based on the function of six key organ systems: respiratory, cardiovascular, nervous, hepatic, renal, and coagulation systems. Each of these categories is graded from a score of 0 (no or minimal organ dysfunction) to 4 (severe organ dysfunction), based on predefined cutoffs that are easily measured in the intensive care unit (ICU). For the respiratory system, the score is based on PaO 2 /FiO 2 (PF) ratios and the need for mechanical ventilation; for the coagulation system, it is based on platelet counts; for hepatic function, it is based on serum bilirubin; for the cardiovascular system, it is based on arterial blood pressure and the need for vasoactive drugs; for the central nervous sys-tem, it is based on the Glasgow coma score; and for the renal system, it is based on serum creatinine and urine flow.
A limitation to using SOFA scoring on a daily basis is the need to obtain the pertinent laboratory data each day. Although this is not necessarily a problem with daily venous blood sampling that is common in most ICUs, measurements of arterial oxygenation to calculate PF ratios are often not done routinely. Thus, the PF ratio component of the SOFA score is often missing. An alternative approach is to use pulse oximetry assessments of oxyhemoglobin saturation (SpO 2 ) as a substitute to then calculate a SpO 2 /FiO 2 (SF) ratio. However, although the relationship of SpO 2 to arterial PaO 2 is generally good, inaccuracies can exist (2) . Furthermore, substituting SF ratios in critically ill patients for the purpose of defining SOFA scoring cut-points has not been systematically studied. The closest attempt at this was the study by Rice et al (3) who defined SF cut-points for defining acute lung injury and the acute respiratory distress syndrome.
In this issue of Critical Care Medicine, Pandharipande et al builds on the Rice approach by studying a large sample of critically ill patients with 2986 matched arterial blood measurements of PaO 2 and pulse oximetry (4). These data were supplemented with 1742 matched samples from patients undergoing general anesthesia. SF and PF ratio values were then calculated, and linear modeling was used to calculate SF threshold values correlating with PF ratios of 100, 200, 300, and 400 (the cut points in the SOFA score calculation). Importantly, data points with SpO 2 values Ͼ98% were excluded. This is reasonable to do to minimize errors on the upper flat portion of the oxyhemoglobin dissociation curve (e.g., an SpO 2 of 99% on an FiO 2 of 0.5 [SF ratio ϭ 199] could represent PaO 2 values ranging from 95 to more than 300 mm Hg [PF ratios of 190 to 600]). This underscores an important limitation to the use of SF ratios in welloxygenated patients breathing high inspired oxygen concentrations.
The authors found good (but not great-Spearman's rho, 0.50) correlation between the respiratory SOFA score calculated with SF vs. the score calculated with PF. They then analyzed this relationship in patients requiring different levels of positive end expiratory pressure and found statistically different (but likely clinically unimportant) SF-PF correlations depending on positive end expiratory pressure level. It is unclear to me why this was the only subgroup analysis done. Specifically, positive end expiratory pressure (by enhancing alveolar recruitment) could affect FiO 2 requirements but this should affect SF and PF values similarly. Furthermore, intrathoracic pressure (unless sufficiently high enough to affect cardiac output) should have no impact on the relationship of PaO 2 to SpO 2 . It would seem to me that more appropriate subgroup analyses should have focused on things that do affect the PaO 2 -SpO 2 relationship such as body temperature, skin pigmentation, peripheral perfusion, and vasoactive drug use (2) . The authors reason-ably argue that while incorporation of these covariates might have strengthened the model, it also might have made the regression equation difficult to use clinically. However, we really will not know this until specific analyses such as these are done.
At the end of the day, the value of this study is borne out in the prospective validation of the SF-derived SOFA scores in subsequent ICU patients. In this phase of the study, the respiratory component of the SOFA score and the total SOFA were calculated in a cohort of 100 trauma and surgical ICU patients using both the SF and PF ratio thresholds. Both approaches yielded similar correlations with important outcomes, such as ICU length of stay and ventilator-free days. The authors thus reasonably conclude that SF ratios provide an alternative method for calculating the respiratory component of the SOFA score when the PF ratios are unavailable because of the lack of arterial blood gas data. Extension of this work would allow the SF-PF correlation to be applied to other clinical scoring systems that also require a PF ratio for their calculation.
This should not be the end of the story. Although one of the strengths of this study is its large, heterogeneous group of patients (and thus its generalizability), the statistically significant r 2 values for the SF and PF correlations are still lower than clinicians would like to see in surrogate data. As noted earlier, more in-depth analyses of factors affecting SpO 2 -PaO 2 may further enhance the utility of the SF ratio in clinical scoring systems.
Neil MacIntyre, MD Department of Respiratory Care
Duke University Medical Center Durham, NC
A new twist on the legend of granulocyte colony-stimulating factor in acute lung injury?* G ranulocyte colony-stimulating factor (G-CSF) is a potent neutrophilic growth and release factor. Too low or relatively too low levels of G-CSF may make the host susceptible to progression of an infectious insult, such as sepsis or pneumonia. However, too high or relatively too high levels of G-CSF may result in an overzealous inflammatory response, potentially causing more harm than the original (infectious) insult itself. G-CSF is associated with an altered circulating neutrophil phenotype similar to that seen in acute lung injury (ALI) patients (1) (2) (3) (4) . Furthermore, high plasma and bronchoalveolar lavage fluid (BALF) G-CSF levels are present in patients at risk for ALI (5, 6) , and BALF G-CSF levels correlate with the severity of lung injury (6) and risk of death (7) .
To evaluate the association between plasma G-CSF levels and clinical outcomes in patients with ALI and to determine whether lower tidal volume ventilation was associated with a more rapid decrease in plasma G-CSF levels over time, Surrat et al (8) measured G-CSF in plasma of 645 patients enrolled in the ARDS Network trial of lung-protective mechanical ventilation using lower tidal volumes compared with conventional mechanical ventilation using traditional tidal volumes for ALI. Surrat et al found baseline plasma G-CSF levels to be associated with an increased risk of death and a decrease in ventilator-free and organ failure-free days: stratification of plasma G-CSF levels into quartiles revealed a strong association between the highest plasma G-CSF level and increased risk of death and decreased ventilator-free and organ failure-free days. Patients with sepsis as the cause for ALI revealed a U-shaped association between mortality and plasma G-CSF levels: risk of mortality increased linearly from the second through highest quartiles, but risk was also increased in the lowest quartile. Plasma G-CSF level profiles over time, however, were found not to differ between ventilator strategies indicating no effect of tidal volume size with mechanical ventilation for ALI. G-CSF-friend or foe in ALI? In the analysis of the whole cohort of ALI patients by Surrat et al (8), a similar association between elevated plasma G-CSF levels and clinical outcomes was found as previously reported for other cytokines (9, 10) . Together with the suggestion that G-CSF may promote ALI (11), one thus might conclude G-CSF to be a foe in patients with or at risk for ALI. However, the subanalysis separating patients with indirect ALI from patients with pneumonia suggests this may not be true, at least not completely. Indeed, although the subanalysis did show a significant relationship between the highest quartile G-CSF levels and worse outcomes in patients with indirect ALI, it also showed a much weaker association between plasma G-CSF levels and outcomes in patients with direct ALI (i.e., pneumonia). The finding that plasma GCS-F levels over time did not differ between patients ventilated with lower tidal volumes and patients ventilated with traditional tidal volumes further suggests that G-CSF does not play a role in ALI per se. In case there would be such a role, one would expect a difference over time between the two ventilation strategies, as found for other markers of inflammation (12) . On the basis of the subanalysis by Surrat et al (8) , one thus may also conclude G-CSF to be neither a friend nor a foe, at least in patients with pneumonia as the cause of ALI.
Unfortunately, the original study did not allow collection of BALF. This is rather inopportune, given that the earlier publications suggest a strong association between BALF G-CSF levels and clinical outcomes (6, 7) . Another shortcoming of the study is the fact that the number of patients in the tidal volume cohorts are small, as pointed out by the investigators.
The disappointing results of many immunomodulating strategies for ALI have led to the reconsideration of the pathophysiology of ALI, both in patients with sepsis-induced ALI and patients with pneumonia. Although the possible reasons are numerous, a major factor contributing to the failure of clinical ALI trials probably lies in the heterogeneity of the patient population enrolled, which stems from the lack of tools allowing an effective classification of the patient's immune status and thus appropriate medical decision making. Currently available tools for therapy management by clinicians yet only comprise symptom classification systems. These systems, however, are only validated for outcome predictions in large populations and not for individual patients. To address the complexity of ALI and to predict its outcome, multiple surrogate markers that reflect the nature and severity of the inflammatory response and the magnitude of lung injury are likely to be more effective in identifying patients at risk of an adverse outcome and who may benefit from interventional therapies. Such strategies will inherently require the use of multiplex approaches providing insight into a patient's inflammatory and immune status.
Probably, G-CSF may only be one of the many surrogate markers to guide immunomodulating strategies for ALI. Of importance, this investigation suggests diverse roles for G-CSF in indirect ALI and pneumonia. Other investigations point at the possibility of differences in G-CSF gene expression (13) , and polymorphisms of the promoter region of the gene encoding G-CSF, which all have to young and elderly humans. 
Trauma computed tomography and radiation dose: A matter of concern*
A good dictum for the adoption and deployment of a promising technology-one often unheeded but almost always inevitable-is that if it is beneficial in the near term it will also bring about unforeseen, unintended, and damaging consequences in the medium term and beyond. Therefore, every blessing of science and engineering is mixed, a blend of the life enhancing with the noxious. Thus, fossil fuel energy begat global warming, antibiotics begat Clostridium difficile diarrhea and computed tomography (CT) scanning, used excessively, will most likely begat radiation-induced cancer.
That CT scanning for trauma and otherwise is overused in the United States is undeniable. In 1980, two million examinations were performed throughout the nation. In 2003, 65 million were performed (1) . The number of Americans grew by 30% in that interval and the age structure of the population has not changed much. Many scans performed currently are negative and, a sizeable fraction, are not indicated, according to evidence-based medical criteria. CT studies have increased in dose per scan because of technical innovations. The standard multidetector CT of today allows more slices per body sections and more body sections per examination because of its increased speed (2) . Furthermore, it has made studies of children easier, hence CT volume of young people has proportionately increased even faster than have examinations of adults.
The advantages of the modern multidetector CT are clear for the rapid and incisive assessment of patients with trauma whose entire head, neck, and trunk can now be surveyed within one breathhold. Furthermore, the ease of performance of these devices enables more scans to be completed, both as part of an initial evaluation and for later monitoring during one trauma hospital stay. Furthermore, they can be readily repeated for each subsequent admission over a lifetime. Yet, hidden in the enthusiasm for CT and only now becoming an emerging concern are the deleterious effects of radiation. This consequence is especially likely if dose deposition is large. Yet, it will be delayed often for decades so that there is a disconnect in time and personnel between the present trauma and the later appearance of cancer.
In this issue of Critical Care Medicine, Salottolo et al addresses these issues head on (3). The authors have endeavored to calculate effective dose of radiation received by two groups of patients during monthly intervals in 2003 and then in 2007. Considering those who received a dose of Ͼ100 mSv in either time period, they found that patients received more scans in the more recent study period. They then surmised that those receiving an increase in the number of scans were at heightened risk for the development of cancer later in life.
Salottolo et al made some simplifying assumptions whose ultimate value, although probable, are still conjectural. They claim that potential adverse effects for radiation can be extrapolated from simple scan parameters. Well, yes and no. This belief is based on the adverse effects suffered by atomic bomb survivors. But those unfortunate individuals received their dose at one time and much of it involved radiation by high-energy particles (those with an elevated linear energy transfer). On the other hand, successive scans by x-ray photons, which has a low linear energy transfer, allow time for repair, possibly ameliorating the untoward effects of ionizing radiation per exposure (4) . The risk will vary with age, being most significant in children who receive a greater dose, if there is no modification of amperage and time factors in CT protocols. Furthermore, children are also intrinsically more susceptible to radiation per unit dose received than older adults. Also, they will live longer than adults, providing more time for a malignancy to express itself (5, 6) . Surprisingly, children were excluded from this study.
The protocol used at Swedish Hospital, even in 2007, is more constrained than what occurs in many trauma centers, including mine. Today, in most centers, the typical trauma regimen, especially for motor vehicle accident victims, is consecutive scans of the head, neck, chest, abdomen, and pelvis as a matter of course, not as a matter of choice. Thus, dose accumulation is even greater on average than at the authors' hospital. Furthermore, often the thyroid gland is irradiated twice in such sequences because frequently the neck and chest fields overlap. Thyroid cancer is increasing in incidence everywhere in the United States, and radiation has been shown to be a risk factor (7) . Hence, the chest and breast are not the only organs likely to be the site for more malignancies because of contemporary trauma CT utilization (8) .
Salottolo et al of this study should be congratulated for their attempt to provide data for what promises to be a major health concern in both the near and the far future. Iatrogenic cancer will most assuredly be a byproduct of the dark side of the CT revolution.
For the present, the threat imposed by widespread use of CT mandates two immediate responses. For children, modulation of dose is essential. Newer CT scanners have such modifications built in them; users of CT must use them. Also, CT protocols must be examined critically. Not every trauma patient needs a CT study and not everyone who needs one requires a comprehensive scan from head to femur for blunt trauma. Radiation-induced malig- Although outcomes are improving, sepsis currently accounts for the majority of deaths in western intensive care units (1) . In the progression of sepsis to septic shock, intensive care physicians frequently observe a typical hemodynamic response, including reduced systemic vascular resistance and profound arterial hypotension (2) . Despite massive fluid administration, patients with sepsis often require vasopressor support with little evidence for the superiority of any drug (3) . During this so-called hyperdynamic phase of septic shock, supranormal cardiac output is often accompanied by signs of persisting tissue hypoperfusion. Elevated lactate levels together with reductions in arterio-venous oxygen extraction are metabolic indicators of a distributive defect of blood flow and thereby oxygen through the microcirculation (4). These alterations have long been known; however, a direct proof of shunting in septic shock is lacking. Pioneering studies using orthogonal polarization spectral imaging, which can directly visualize small vessels and capillaries in real time elucidated the presence of massively al-tered microvascular perfusion in septic shock (5) . Persistence of impaired microvascular blood flow is associated with a fatal outcome (6) . These deficits would explain some of the above-mentioned characteristics. In this context, monitoring of the microcirculation might display an attractive measurement site, because unlike systemic variables it pinpoints the vascular interface where blood and thereby vital substrates are delivered to the capillary exchange beds.
In this issue of Critical Care Medicine, Bü chele et al (7) investigated the shortterm effects of hydrocortisone (HC) on global hemodynamic parameters, oxygen-derived variables, and the microvascular response in 20 patients with early septic shock. HC was administered every 6 hours at a dose of 50 mg. Microcirculatory flow was assessed at the lateral side of the tongue and quantified using a semiquantitative score. Although the authors found no significant changes in systemic hemodynamics, there was a significantly higher proportion of small vessels (i.e., capillaries) perfused already 1 hour after HC administration. Although the authors admit that possible explanations can only be speculative, the study is important because it demonstrates that therapeutic interventions can influence the microcirculation independent of systemic variables. Admittedly, in the present study only a small number of patients were investigated over a relatively short period. In addition, the majority of patients were male, which might have influenced the microvascular response to HC because of varying estrogen levels (8) . Although the impact of HC in septic shock remains controversial, its use in the most severe cases is recommended. The present study suggests that HC does not negatively influence microvascular blood flow in these patients.
The authors are to be congratulated for their continuing effort in investigating the mechanisms that underlie the distributive defect in septic shock.
But what comes next? The accumulated literature on the presence of microvascular alterations in septic shock, experimentally and clinically, is convincing (5, 6, 9, 10) . Pathophysiologically, measurements of the microcirculation seem to be of paramount importance, especially in septic (distributive) shock, and have promise to augment classic hemodynamic monitoring. But what comes next? Besides these fascinating pictures of red blood cells moving (or not moving) through the smallest vessels which always amaze the audience of intensive care meetings. What comes next? We need prospective trials in large patient populations to further investigate the nature and significance of microvascular abnormalities in septic shock and its influence on the course of the disease and ultimate outcomes, respectively. Furthermore, the impact of underlying diseases, the effect of fluids and vasoactive treatment, and the relation of the microvasculature to macrohemodynamic changes need to be elucidated. Finally, on the basis of these findings, therapeutic concepts aiming to restore microvascular blood flow can be implemented and tested for their superiority over current treatment strategies. The initiative of several investigators who informally met during the 2008 International Symposium on Intensive Care and Emer-gency Medicine in Brussels to form an international collaboration with the aim to address these challenges in a multicenter study with participants from 30 centers and 4 continents is, therefore, greatly appreciated. This impressive number reflects the enthusiasm of all collaborators, which is definitely needed if we want to see microvascular imaging to become a crucial element of hemodynamic monitoring in the future.
Michael 
Norepinephrine in anthrax-associated shock: Even worse than figs?*
A nthrax is an anthropozoonotic disease caused by a Grampositive, spore-forming bacterium (Bacillus anthracis) that belongs to the Bacillus cereus group (1) . First reports of the disease date back to the ancient Egypt where anthrax is suspected to have caused the fifth and sixth of the ten biblical plagues. It was also the bible that mentioned the earliest known drug to heal anthrax. Although evidence must be graded as level III or expert opinion, biblical passages indicate that figs have healing properties in cutaneuos anthrax lesions (2) . Since comprehensive animal vaccination programs have been introduced, human anthrax cases are only sporadically observed (1, 3) and have become medical curiosities for most of the critical care clinicians in industrialized nations. Even though as many as 100,000 cases of human anthrax are estimated to occur annually worldwide (4), only the tragic infection of 22 patients in a bioterroristic assault in the United States in October 2001 has brought renewed interest in anthrax to the Western medical literature (5) .
Infection with Bacillus anthracis or its toxins consisting of three proteins (protective antigen, edema factor, lethal factor) usually occurs by skin contact, ingestion, or inhalation of anthrax spores. Accordingly, three forms of anthrax are commonly encountered. Cutaneous anthrax represents the mildest form and is usually restricted to the skin with unspecific systemic manifestations like headache, malaise, or fever. Pulmonary and gastrointestinal anthrax, on the other hand, are severe manifestations of Bacillus anthracis infection and are associated with mortality rates of up to 100%. Anthrax meningitis is a rare complication of any of the three disease manifestations (1) . In endemic regions where anthrax almost exclusively occurs after transmission from animals to humans, the cutaneous form prevails (6, 7) . After bioterroristic assaults, inhalation of spores and inhalational anthrax is the most common way and form of infection, respectively (5, 8) . The diagnosis of anthrax must be based on a high amount of suspicion and aggressive use of screening tests (1, 4) .
Assuming that ϳ5% of all anthropozoonotic anthrax cases are either pulmo-nary or gastrointestinal forms with mortality rates of 80% to 100% (7) , nearly 5000 patients annually die of anthrax worldwide. Because these cases usually occur in endemic regions of less developed parts of the world (6, 7) , little attention has been paid by the Western literature and even fewer lessons have been drawn from these deaths. During the October 2001 bioterroristic anthrax assault in the United States, modern critical care medicine was thus confronted with lethal anthrax more or less for the first time (5, 8, 9) . The clinical course and major symptoms of the five patients who succumbed to anthrax during the 2001 outbreak in the United States are reviewed in Table 1 . Table 2 summarizes the recommendations for the management of anthrax infection, which were released by the Center of Disease Control and Prevention in 2001 (10) and updated in 2008 (11) .
The scarce current knowledge on anthrax-associated shock suggests that it represents a noncytokine-mediated hypotension (12) and shares few similarities with "common" septic shock. Is anthrax a different kind of sepsis? It very much looks like. Two exotoxins of Bacillus anthracis have been implicated in anthraxassociated shock. Although in an animal experiment, edema toxin, a complex of the protective antigen and the edema factor, was ϳ10 times less lethal than the lethal toxin (a complex of protective antigen and lethal factor), it produced greater hypotension and contributed to the harmful effects of lethal toxin (13) . Another animal study reported that lethal toxin primarily reduced left ventricular systolic function, whereas edema toxin decreased vascular tone and thus relevantly contributed to hypotension (12) . Despite these striking findings, little is still known about the pathophysiology of anthrax-associated shock. Similarly, the efficacy of specific therapeutic interventions to treat anthrax-associated shock has only been studied insufficiently. In contrast to septic shock (14) , fluid resuscitation, surprisingly, did not improve outcome in rats after injection of anthrax lethal toxin (15) .
In this issue of Critical Care Medicine, Li et al (16) , the critical care expert group on anthrax research led by Dr. Eichacker present a large animal study evaluating the effects of norepinephrine on arterial blood pressure and survival after anthrax lethal toxin injection. In 232 Sprague-Dawley rats, the effects of a 24-hour infusion of three different norepinephrine dosages were compared among animals challenged with lipopolysaccharide or anthrax lethal toxin. In both study groups, the effects of norepinephrine were further compared with a placebo infusion. Once again, the authors observed striking and unexpected results. Although norepinephrine, at least at its intermediate and clinically relevant dosage, improved survival in lipopolysaccharide-challenged rats, there was an increase in arterial blood pressure during three differently dosed norepinephrine infusions but no benefit on survival in anthrax lethal toxin-infused animals.
Taking these and the authors' former observations on the effects of fluid resuscitation on survival of anthrax lethal toxinchallenged rats together, their results support the clinical observation that once shock after anthrax infection has developed death is very likely to ensue despite aggressive hemodynamic therapy (5, 8, 9) . Another interesting observation of this study was that anthrax lethal toxinchallenged animals did not show a pronounced increase in circulating norepinephrine, epinephrine, and nitric oxide levels as observed in rats receiving lipopolysaccharide. This again supports the hypothesis that anthrax-associated and lipopolysaccharide/septic shock underlie different pathophysiologic mechanisms (12) making a different therapeutic approach for both shock types extremely likely.
As with any animal experiment, there are important limitations when extrapolating its results to the clinical setting. The most important limiting factor may be that the authors challenged the study animals with anthrax lethal toxin alone. From the above-mentioned research (12, 13) , we have learnt that not only lethal toxin but particularly edema toxin contributes to the development of anthraxassociated shock. Furthermore, the infused lethal toxin is primarily responsible for direct cytotoxic effects of anthrax (1), and thus rather for induction of myocardial dysfunction (12) than loss of vascular tone requiring a vasopressor drug. It is, therefore, conceivable that evaluating the effects of norepinephrine in another animal model challenged either directly with anthrax spores or with both lethal and edema toxin may have rendered different results more close to the clinical scenario. Another limitation may be that for given reasons the author used a fixed instead of a titrated norepinephrine dosage regimen. This raises the possibility that at least some animals may have experienced an overshooting vasoconstrictive response and thereby critically decreased their systemic blood flow and oxygen delivery. However, none of these considerations can oppose the principal findings of the authors. Anthrax lethal toxin seems to cause direct cellular injury insensitive to norepinephrine therapy. Therefore, no fluids and no vasopressors in patients with anthrax-associated shock? As the authors state, this cannot be the solution! Hypotension and tissue hypoperfusion cause organ ischemia, dysfunction, and failure in all organisms independent of anthrax infection. Norepinephrine may obviously not be effective to partly reverse cellular injury in anthrax infection as it does in septic shock (14) , but it can clearly prevent further harm that is superimposed by untreated hypotension. The results of this study should urgently stimulate further research on the pathophysiology and hemodynamic management of anthrax-associated shock and must not let therapeutic nihilism spread among critical care clinicians when it comes to the hemodynamic therapy of anthrax-infected patients. In contrast, critical care clinicians all over the world must realize that there is more to the management of anthrax-associated shock than use of fluids and vasopressors alone. It looks like these treatments need to be combined with more effective and causatively active steps such as antibiotics (Table 1 ) and probably toxin-binding treatments (17, 18) . These therapies must be made available to sufficiently protect the civilization in the industrialized nations from potential and, hopefully never again, occurring bioterroristic anthrax attacks, and to the critically ill anthrax patients in developing countries who currently die in silence and unnoticed by the Western critical care community.
Christian The use of early, aggressive serial, or continuous drainage of pleural effusions is recommended for all inhalation anthrax cases. a Cutaneous anthrax with signs of systemic involvement, extensive edema, or lesions on the head or neck requires intravenous therapy, and a multidrug approach is recommended; b for localized or uncomplicated cases of naturally acquired cutaneous anthrax, treatment courses of 7-10 days are recommended, but 60 days is recommended in the setting of a bioterroristic attack, given the likelihood of exposure to aerosolized Bacillus anthracis; c doxycycline dosages for children: Ͼ8 yrs and Ͼ45 kg, 100 mg bid; Ͼ8 yrs and Ͻ45 kg, 2.2 mg/kg bid; Ͻ8 yrs, 2.2 mg/kg bid; d severe illness is considered as inhalation anthrax, gastrointestinal anthrax with systemic involvement, cases with suspected meningeal involvement, or fulminant cases with bacteremia; e other agents with in vitro activity against Bacillus anthracis include rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, clindamycin, and clarithromycin. Because of concerns of constitutive and inducible beta-lactamases in Bacillus anthracis, penicillin, and ampicillin should not be used alone. Consultation with an infectious disease specialist is advised; f if meningitis is suspected, antimicrobials with adequate central nervous system penetration need to be chosen; g switch from intravenous to oral antimicrobial therapy when clinically appropriate; h postexposure prophylaxis is only indicated during bioterroristic attacks; i anthrax vasccine adsorbed ͓BioThrax (BioPort Corporation, Lansing, MI)͔ should be administered at time zero, 2 wks, and 4 wks. Anthrax vaccine adsorbed is not FDA approved for postexposition prophylaxis, and therefore would be available under an Investigational New Drug protocol. Currently, anthrax vaccination cannot be recommended for use in children because safety and efficacy data are lacking; j although the Department of Defense has published safety data on anthrax vaccine adsorbed during pregnancy, the statistical power of the study was limited. It was proposed that anthrax vaccine adsorbed be included in the postexposure prophylaxis protocol for pregnancy, if there is strong evidence of risk for inhalational anthrax or if the benefit outweighs risks from vaccination. Should zinc status be monitored and deficiency treated in critically ill patients?* C linicians have traditionally concentrated on macronutrients, in terms of optimal calorie and protein requirements, when considering the metabolic and nutritional support of critically ill patients. Attention to micronutrients, both vitamins and trace elements, is often neglected. A recent publication from a major American university concluded that there is substantial discordance in practice patterns, indicating an urgent need for nutrition-related education at all levels of physician training (1) . In this issue, Knoell et al (2) report a study in a murine model, highlighting the importance of zinc (Zn) in decreasing mortality in polymicrobial sepsis. This will hope-fully stimulate interest among critical care specialists on the importance of micronutrients.
Mice were assigned to three groups: control diet, Zn-deficient, and Zn-deficient followed by oral Zn supplementation for 3 days. The cecal ligation and puncture technique was used for the sepsis model. Mortality from sepsis was increased in animals with Zn-deficient. Supplementation of Zn decreased mortality, normalized the inflammatory response (as measured by a variety of markers), and diminished tissue damage mainly in the lung. This is the first study to show that in an animal polymicrobial cecal ligation and puncture sepsis model, a deficiency of Zn increases mortality and conversely supplementation of high doses of Zn decreased mortality.
However, animal models may not always be applicable to humans. Although cellular and serum markers are used in human studies as surrogates for beneficial effects, the effect on infectious and noninfectious complications, length of stay, duration of ventilatory dependence, and so forth are more convincing. The effect of Zn supplementation in humans on mortality as such has not been studied adequately and is an area open to research. Until this is available, valuable information can be obtained from the Knoell study hopefully leading to better patient care. However, it is to be noted that the dose of Zn supplementation used in this study was 100 mg/kg, which amounts to 7000 mg for an average 70-kg patient, far greater than the recommended daily enteral intake of 8 -11 mg/ day (and of which only 1-2 mg is absorbed, mainly in the duodenum). Such high doses of trace elements can no longer be considered supplemental but pharmacologic. In humans, the recommended parenteral dose of Zn is 2.5-4 mg/ day, although up to 20 mg/day may be administered to compensate for gastrointestinal (GI) losses. At these recommended doses, there is absolutely no risk of toxicity, given that Zn is excreted in GI secretions. Higher intake of Zn (150 mg/day for 6 weeks) may be detrimental by impairing immune responses (3) . When human trials are conducted in the future, the dose of Zn used must be carefully considered for safety. The clinician is reminded that commercially available 220 mg zinc sulfate tablets contain 50 mg of elemental Zn each.
The five important essential trace elements approved by the Food and Drug Administration for parenteral use are as follows: Zn, selenium, copper, chromium, and manganese. Of these, Zn is the most abundant in the body, mostly intracellular, with a role in the function of more than 70 metalloenzymes, of which the most familiar to clinicians are carbonic anhydrase, alkaline phosphatase, superoxide dismutase, and angiotensin-converting enzyme. Zn has been well studied in epidemiology and in clinical conditions. Its role in wound healing has been appreciated for many years and hence its extensive use in burns (4) . Patients who are at risk for Zn deficiency at the time of admission include elderly patients from long-term care facilities, alcoholics, and prolonged GI losses. Patients who develop GI fistulas, severe diarrhea, short bowel syndrome, pancreatic insufficiency, high dose of steroids (possibly due to proteolysis), and those with bile leaks during the course of treatment are also at high risk for developing Zn deficiency. Other conditions include human immunodeficiency virus, trauma, burns, and malignancies (5) .
How does Zn deficiency manifest in the critically ill patient? In addition to its well known effects on poor wound healing, the commonest clinical manifestation seems to be a peculiar skin rash (scaly, hyperpigmented lesions involving elbows and knees) originally described as "acrodermatitis enteropathica" (6) . The rash is also often seen on the face around the ala nasi and gluteal areas. Other manifestations include glucose intolerance, abnormal hemostasis, loss of hair, altered taste and smell perception, and diarrhea. Zn deficiency causes decrease in work capacity of muscles with detrimental effects on respiratory function (7) , has been shown to increase respiratory infections (8) , and worsens hepatic dysfunction (9) . Given the important role of Zn in several enzymes, it is not surprising that deficiency results in a multitude of clinical manifestations.
As subtle clinical findings can be missed, and as skin rash may have other etiologies, we need laboratory tests to ascertain Zn status. Here lies the problem in clinical practice. Determination of Zn status is fraught with difficulty as in the case of all trace elements. Collection using special trace-element-free equipment into special tubes is needed. Specimens often need to be sent to specialized reference laboratories with significant delay in obtaining the results. Serum levels do not always reflect intracellular levels. Additionally, serum levels can decrease because of situations unrelated to Zn intake or status, such as stress and infections, where it is believed that intracellular Zn concentration increases. Analysis of Zn-binding proteins such as metallothionein (also studied by Knoell) in alternative tissues, such as blood cells and hair, have been tried, but a large reliable assessment tool for Zn status is still elusive (10) . Zn kinetic studies using isotopes of Zn such as 65 Zn are not practical in the clinical setting (11, 12) . However, despite these limitations, serum Zn level, although representing only 0.1% of total body Zn, is the best clinical test we can offer our patients. When Zn status is shown to be deficient, or when the risk of Zn deficiency is high based on clinical evaluation, patients need Zn supplementation orally or via the enteral or parenteral route.
In summary, the study by Knoell highlights the importance of Zn in the care of critically ill patients. In answer to the question raised in the title of this editorial, clinicians must monitor the Zn status of critically ill patients at risk for Zn deficiency. Administration of Zn is indicated where serum levels are low. Additional amounts are needed in patients with excessive GI losses. Krishnan 
Platelet activation as a direct and indirect cause of acute lung injury during inflammatory disorders*
I t is increasingly recognized that in addition to aggregation and thrombus formation, platelets have a role in inflammatory responses such as those caused by lung ischemia-reperfusion (1) and are associated with tissue injury in a number of vascular beds. Activated platelets, as well as leukocytes, adhere to the endothelium and release cytokines and other mediators, which propagate endothelial damage resulting in vascular dysfunction (2, 3) . In the lung, although leukocytes may be activated at an early stage in the inflammatory process, sequestration generally develops over several hours (4) . This finding helps to explain an early neutrophil-independent, and later neutrophil-mediated, increase in permeability with lung ischemia-reperfusion (5, 6) . During early reperfusion of postischemic ventilated lungs, P-selectin-dependent platelet adhesion occurred along pulmonary arterioles and was associated with decreased arteriolar diameter and reduced alveolar perfusion (7) . Platelet rolling and adhesion were observed independently of leukocytes and were correlated with inducible nitric oxide synthase expression/ activity and reactive nitrogen species formation (8) . Because physiologic amounts of nitric oxide inhibit platelet activation by down-regulating P-selectin (9), bioavailability of nitric oxide can modulate plateletmediated responses. Reactive oxygen species released by activated platelets, as well as by neutrophils, macrophages, and other cells, is an important causative factor in acute lung injury (10, 11) and indicates that platelet-endothelial adhesion can injure cells and tissues directly, compromising pulmonary vascular regulation.
In the current issue of Critical Care Medicine, Asaduzzaman et al (12) report that platelets have a significant proinflammatory role in sepsis-induced lung injury by activating and priming neutrophils that are subsequently recruited to the lungs. With a model of abdominal sepsis in mice that was initiated by cecal ligation and puncture, they convincingly showed that pulmonary injury was associated with neutrophil infiltration, increased chemokine levels, and pulmonary edema. Membrane-activated complex-1 (Mac-1) expression on neutrophils was upregulated and the number of circulating neutrophils bound to platelets increased. Involvement of platelets in the neutrophil recruitment and lung damage was shown by the finding that A plateletdepleting antibody, given before cecal ligation and puncture, reduced lung damage and edema, neutrophil recruitment, and Mac-1 expression on neutrophils. Platelet depletion, however, did not affect the production of the chemokines, macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant in the lung, or the levels of circulating leukocytes. Antibodies against Mac-1, reduced neutrophil recruitment in the lung, but did not change the percentage of neutrophil-platelet aggregates in the circulation. Although antibodies against P-selectin-glycopreotein-ligand-1 decreased the cecal ligation and puncture-induced neutrophil-platelet aggregation, they had no effect on Mac-1 expression. From these results, it was concluded that in abdominal sepsis, platelets can regulate neutrophil infiltration in the lungs via upregulation of Mac-1.
Platelets have a significant role in inflammatory interactions with leukocytes (13) , and platelet-leukocyte-endothelial interaction (3) is certainly an important mechanism of acute lung injury. Platelets and neutrophils bind to the endothelium when activated, and also interact with each other, forming aggregates. The work by Asaduzzaman et al (12) extends find-ings that platelets are involved in activating or recruiting leukocytes and may modulate their behavior (14) . Their results are also consistent with those from a model of acid-induced acute lung injury in mice, where platelet-neutrophil interactions were associated with increased permeability and decreased gas exchange (15) . These effects were attenuated by reducing circulating platelets, blocking P-selectin, or by inhibiting plateletneutrophil aggregation. Activated platelets increased neutrophil adhesion by inducing expression of intercellular adhesion molecule-1 on endothelial cells. Furthermore, in zymosan/lipopolysaccharide-induced sepsis, platelet-neutrophil interactions caused similar lung injury, which could be reduced by platelet depletion before sepsis. Although current evidence indicates that platelet adhesion to leukocytes and endothelial cells plays a key role in acute lung injury caused by inflammatory disorders, much less is known about the mechanisms by which platelets activate leukocytes.
A strength of the well-designed study by Asaduzzaman et al (12) to examine the role of platelets on neutrophil recruitment is that it evaluated several mechanisms by which platelets could influence leukocyte recruitment during sepsis. Interestingly, platelet-mediated Mac-1 expression did not appear to be dependent on contact formation between neutrophils and platelets, and neutrophilplatelet aggregates did not preferentially accumulate in the lung. However, there was strong evidence that platelet-induced activation of circulating leukocytes facilitated leukocyte interactions with the endothelium in the pulmonary vasculature. A remaining question regarding plateletmediated activation of leukocytes concerns the possible contribution of adhesion-independent events via secretion of platelet-derived (or other) substances. Both adhesion-dependent and adhesionindependent mechanisms may be involved. Platelet depletion reduced neu-trophil infiltration and protected against sepsis-induced lung injury. It is also possible that some tissue injury was mediated directly by platelets, and detection may depend on the time course after cecal ligation and puncture and type of measure of lung injury or response. Activated platelets release substances that can up-regulate expression of cytokines, and platelets can deposit proinflammatory compounds on the endothelium that could have effects, as the authors discussed.
This investigation (12) is a significant advance because it provides a better understanding of the complex interactions between platelets and neutrophils and how these interactions cause lung injury associated with abdominal sepsis. Questions remain about the ability to prevent injury after induction of sepsis when neutrophils are recruited to the lung. Further research is needed to improve therapeutic strategies for this and other inflammatory lung diseases associated with a high morbidity and mortality. Potential therapeutic interventions include inhibition of platelet-leukocyte aggregates and their endothelial adhesion by blocking selectins and the ligands responsible for their initial adhesive interactions, or blocking integrins, involved in their firm adhesion. Other strategies include blockade of proinflammatory mediators and downstream signaling pathways that are activated by platelet and leukocyte interactions. Overall, it appears likely that the relative importance of different adhesion molecules or mediators will vary at differ-ent stages of injury, depending on the dominant component. Unanticipated side effects may occur with nonspecific blockade or inhibition of pathways due to the widespread actions that many of the targets and signaling components have. Platelets, with their role in hemostasis, and the Mac-1 leukocyte receptor, with its role in other leukocyte interactions, are examples. Therefore, as specific mechanisms of platelet interactions are elucidated, selective targeting to block activated receptors and pathways has promise for new effective ways for the critical care practitioner to treat inflammatory lung disease.
Andrew M. Roberts Caffeine-stimulated mechanisms for improved cardiac function during sepsis* S epsis-associated myocardial dysfunction has been long reported in experimental and clinical studies, although the mechanisms for this phenomenon have not been completely resolved. Significant evidence has been reported, suggesting a sepsis-induced metabolic defect is likely to underlie myocardial dysfunction. Verma et al (1) demonstrated that myocardial cytochrome oxidase (COX) activity, the terminal oxidase of the electron transport chain, was depressed by cecal ligation and puncture in rats, coincident with decreased cardiac performance and lethality. Caffeine increased COX activity concomitant with increased cardiac function and survival.
Caffeine (1,2,7-trimethylxanthine) is a natural compound found in cocoa beans, cola nuts, coffee, and tea and is highly membrane permeable. Its medicinal character has been long understood by humanity, its psychoactive character helped build the modern industrial society we live in now (2) . Without it, how could I write this review?
Caffeine has been documented to have many biological effects; including antagonism of adenosine receptors, alteration of dopamine 2 receptor and COX 1, 4, and 7c expression (3), regulation of adenosine triphosphate-sensitive K ϩ channels (4), inhibition of phosphodiesterase (5), release of intracellular Ca 2ϩ , and activation of protein kinases that can mediate physiologic effects as diverse as facilitation of voluntary movement by altering basal ganglia physiology (3), decreasing myocardial blood flow reserve (6) , regulating insulin secretion, vascular tone, heart rate, and neuronal excitability by re-sponding to transmitters as well as the internal metabolic state (4) .
The character of myocardial depression in sepsis has been studied in animal models (7) and clinical studies (8, 9) for Ͼ50 years. Much confusion has been generated by the dichotomy of ventricular performance and contractility, the inherent ability of the heart muscle to contract (10, 11) . Patients with septic shock develop a hyperdynamic (high volume output and high performance) circulatory state after fluid resuscitation and maintain this hyperdynamic circulatory state until death or recovery. However, myocardial depression (reduced contractility), is demonstrated by biventricular dilation and reduced ejection fraction in most patients with septic shock; findings that are reversible over the course of 7-10 days in survivors (9) .
Numerous mechanisms mediating loss of myocardial contractility in sepsis and models of sepsis have been proposed; a complete review of these is beyond the scope of this comment. It has long been recognized that depressed mitochondrial function would be a logical mechanism for sepsis-induced myocardial depression. Levy (13) recently reviewed evidence supporting the concept that mitochondrial dysfunction is pathogenic to sepsisinduced myocardial depression. It has been proposed that an acquired defect in oxidative phosphorylation prevents cells from using molecular oxygen for adenosine triphosphate production and potentially causes sepsis-induced organ dysfunction. He concluded that mitochondrial dysfunction and impaired oxidative phosphorylation are established features in heart during sepsis. No clear etiology for reduced enzyme content has been established, but reduced bioenergetic capacity and reduced total mitochondrial content have been reported in the septic heart after cecal ligation and puncture. Endogenous production of a variety of inhibitors during sepsis likely contributes to and causes COX inhibition, which may lead to cellular metabolic downregulation and pathologic hibernation. At the organ level, this down-regulated state manifests as organ dysfunction and may underlie multiple organ dysfunction syndrome. Levy suggested that further evaluation of COX and its inhibitors in sepsis, however, may lead to novel therapeutic interventions aimed at preventing and overcoming this inhibition. Verma et al (1) tested one novel therapeutic, caffeine, and determined that sepsis-induced myocardial depression related to depressed COX activity was reversible by caffeine.
Alternative mechanisms for mitochondrial dysregulation mediating myocardial depression in sepsis have been advanced. For example, Hassoun et al (12) hypothesized that persistent increases in cytosolic Ca 2ϩ concentration, induced by endotoxin challenge, would lead to mitochondrial Ca 2ϩ overload, which can exert detrimental effects on cellular function, impairing oxidative phosphorylation and decreasing energy available to support cellular function.
On the basis of the data presented, several questions arise and deserve additional investigation. Caffeine is a drug that has multiple actions in vivo, distributed over numerous cell types and organs. The authors discuss that caffeine's effect to reverse sepsis-induced COX inhibition may be due to numerous mechanisms, including inhibition of cyclic adenosine monophosphate-phosphodiesterase, increased circulating epinephrine, alteration of intracellular Ca 2ϩ physiology, or antagonism adenosine receptors. Future experimentation should define the mechanisms responsible for the altered physiology observed in this study.
Roy D. Goldfarb (1) . Although the evidence supporting its use during cardiopulmonary arrest is largely based on animal data (3) (4) (5) , the resuscitation of many victims of cardiac arrest would likely not have been successful without this life-saving drug. However, no randomized placebo-controlled clinical trial has been completed documenting the efficacy of standard dose epinephrine during cardiac arrest, and higher doses appear to be deleterious (6 -8) . Therefore, while a little appears to be good, more may not be better.
In this issue of Critical Care Medicine, Ristagno et al (2) invite us to examine the epinephrine effects in an animal model of cardiac arrest to shed further light on this issue. Uniquely, they lead us down a path from the whole animal to the microenvironment. Specifically, they focus at the level of the microvessels. Using orthogonal polarization spectral imaging to measure cerebral cortex microcirculatory blood flow and tissue optical sensors to record cerebral cortical carbon dioxide and oxygen tensions, the effects of epi-nephrine (with and without alpha and beta blockade) were investigated. They concluded that epinephrine through its ␣ 1 agonist action had adverse effects on cerebral microvascular blood flow with resulting cerebral ischemia.
The physiologic basis of resuscitation is to optimize oxygen and metabolic substrate delivery to tissues deprived of blood flow. According to Ohm's law, blood flow (BF) is equal to the upstream pressure (USP) minus the downstream pressure (DSP) (i.e., perfusion pressure, PP) divided by the resistance (R) BFϭ(USPϪDSP)⁄R. Therefore, to increase blood flow to an organ, one can increase the upstream pressure, decrease the downstream pressure, and/or decrease the resistance of the circuit in question. Epinephrine in the intact organism has a host of heterogeneous effects, mediated by ␣ 1 , ␣ 2 , ␤ 1 , and ␤ 2 receptor activation (9) . As a resuscitative medication, epinephrine can, in fact, increase USP, decrease DSP, and decrease R, as well as increase cardiac output and carotid blood flow. For myocardial perfusion during cardiopulmonary resuscitation (CPR), increasing the aortic diastolic pressure is critical for adequate blood flow and effective myocardial resuscitation because forward coronary blood flow is predominantly during diastole (10, 11) . For cerebral perfusion, increasing the mean aortic pressure and systolic pressure is critical for adequate blood flow and effective cerebral resuscitation (12, 13) . However, higher degrees of right heart failure with concomitant increases in central venous and cerebral venous pressures will increase downstream pressure in the brain and decrease flow. Therefore, some of the effects of appropriately dosed epinephrine by decreasing downstream pressure may ameliorate the deleterious effect of right ventricular failure during resuscitation (14) . Although these changes at the level of the macrocirculation are important, what is likely most paramount to preventing tissue level metabolic derangements is allowing the delivered nutrients to actually enter the cell. As a result, resuscitation scientists have turned the focus on attention from optimization of whole body oxygen delivery to cellular oxygen delivery, with a specific focus on cardioprotective and neuroprotective strategies (12, 15) .
Although Ristagno et al should be commended for their efforts to measure circulatory and tissue changes at the microenvironmental level, one must be cautious when interpreting their results. In particular, the clinical implication of microcirculatory changes confined to a small superficial area of the cerebral cortex is largely unknown. Interpreting the meaning of these findings without knowing the circulatory changes at deeper levels of the brain is nearly impossible. More importantly, the findings from this experiment seem to be in direct contrast to a whole host of previous investigations. Numerous studies have documented improvements in cerebral blood flow by microsphere technique with the addition of epinephrine during CPR (14, 16, 17) . Be-cause measurement of cerebral blood flow by microsphere technique depends on trapping the microspheres in the microcirculation, these studies have documented that epinephrine administration during CPR improves cerebral microcirculatory flow. In addition, more recent studies with positron emission technology (18) and arterial spinlabeled MRI (19) have again demonstrated increases in cerebral blood flow during CPR with the addition of epinephrine.
Does this study by Ristagno et al indicate that all of the previous investigations were wrong? Conversely, do the previous studies indicate that Ristagno et al were wrong? We believe that this study adds a new level of granularity to our limited knowledge of this complex area. Although numerous investigations have established that epinephrine can increase cerebral microcirculatory flow over large areas of the brain, the semiquantitative data from Ristagno et al suggest that epinephrine can decrease microcirculatory flow to some areas of the brain and is worthy of further thought.
What are the implications of this study for the clinical intensivist? Despite promising animal data and human hemodynamic data during CPR showing benefits from epinephrine administration, there are no convincing human data demonstrating improved outcomes with epinephrine. Furthermore, Dr. Ristagno's study is not the first to suggest that epinephrine may contribute to poor neurologic outcome following cardiac arrest (2, 20) . Additionally, it is well established that epinephrine during CPR can have adverse myocardial effects, both during CPR and postresuscitation (21, 22) . Nevertheless, increasing aortic diastolic pressures with epinephrine to attain adequate myocardial perfusion is a rational pharmacologic approach that has probably saved quite a few lives. Therefore, rather than blindly following monolithic resuscitation algorithms, maybe we should tailor our treatment based on clinical information available to us at the bedside.
Data from the American Heart Association's National Registry of Cardiopulmonary Resuscitation indicate that Ͼ 35% of children and 17% of adults who suffered an in-hospital cardiac arrest in an intensive care unit had an arterial catheter in place at the time of the arrest (23, 24) (Berg; personal communication). Because clinical data indicate that successful resuscitation is dismal when the coronary perfusion pressure is Ͻ 15 mm Hg, and animal data show a dose-response with increasing survival as coronary perfusion pressure increases from 15 mm Hg to 30 mm Hg, it is reasonable to assume that we should target an aortic diastolic pressure Ͼ 30 -40 mm Hg (25) . If the measured aortic diastolic pressure is Ͼ 40 mm Hg, there is probably no need for a vasoconstrictive agent, and the risks of epinephrine probably outweigh the benefits (26) . In contrast, if the aortic diastolic pressure is 25 mm Hg despite excellent chest compressions, the coronary perfusion pressure will probably be inadequate (Ͻ 15 mm Hg) (27) and a vasoconstrictive agent like epinephrine may be life saving (2, 25, 26, 27, 28 (1) provide the first report describing a stem cellbased strategy for ameliorating brain injury after carbon monoxide (CO) poisoning. By using a rat model, the authors demonstrated that infusing bone marrow-derived stem cells 24 hours after poisoning could diminish CO-induced learning impairment assessed by Morris Water maze tests at 5 weeks postpoisoning, and they also showed that treatments improved brain histology. Benefits followed infusion of bone marrow-derived stem cells into the carotid artery, and somewhat better results were found using bone marrow cells that had been cultured for a period of time ex vivo to induce them to differentiate toward a neuronal stem cell phenotype (MS-NSCs). Infused stem cells were diffusely distributed and could be found in brain areas know to be injured by CO, including the cerebral cortex, hippocampus, basal ganglia, and subventricular white matter. This is an exciting and provocative investigation on many levels. The major conclusion in the article is that infused stem cells are sequestered in the injured brain and these cells seem to mediate improvements of neurologic function.
The authors suggest that MS-NSCs transplants exhibit higher survival rates and terminal neurocyte differentiation vs. bone marrow-derived stem cells. Because the number of transplanted cells is relatively small, they believe that paracrine effects occur wherein the stem cells liberate agents or growth factors that improve function of endogenous brain cells. These ideas are well supported in the literature and there are also alternative possibilities.
Stem cell-based therapies have shown promise for treating acute hypoxicischemic injuries (e.g., stroke), chronic neurodegenerative diseases (e.g., Parkinson's disease), inflammatory disorders (e.g., multiple sclerosis), and even some inborn errors of metabolism (2) . COmediated brain injury does not fit into a single pathophysiologic category. Animal studies indicate that CO poisoning initiates a progressive neuropathologic process with overlapping elements of hypoxicischemic, excitotoxic, and immunemediated brain injury (3) (4) (5) (6) . Therefore, looking at a treatment that supports the injured brain tissue without the need to address primary pathologic mechanisms is attractive.
Numerous approaches have been taken to treat neurologic diseases with stem cells (2) . Neural stem and progenitor cell types, embryonic stem cells, umbilical cord, and also bone marrowderived stem cells have been harvested and sometimes grown ex vivo. They have been delivered by direct injection into brain parenchyma, into the subarachnoid, or the cerebroventricular spaces, or infused by intravenous or intra-arterial routes. Allogeneic approaches are effective, and some studies have shown that autologous cells obtained from an individual's own bone marrow can be effective. Thus, some success was reported using endogenous bone marrow-derived cells mobilized by cytokines and growth factors (7) . Stem cell homing to injured tissues occurs, but the mechanism(s) remain unclear. Stem cells are thought to respond to proteins expressed by injured neurons or other cell types located in the injured brain (2) .
No matter the source or route of administration, stem cells rarely differentiate and replace missing neurons. Rather, stem cells seem to provide trophic support to injured brain tissue by local synthesis of neurotrophins or other growth factors, by stimulating remyelination, by enhancing axonal regeneration because stem cells synthesize a supportive extracellular matrix, or because stem cells produce metalloproteinases that ease passage of regenerating axons through glial scars (8 -10) . Particularly, with rodent models of stroke, coupling between angiogenesis and neurogenesis can be shown. Stem cell-mediated angiogenesis leads to preservation of neurons and improved functional outcome. In some models of inflammatory brain injury, intravenously administered neural progenitors or bone marrow stromal cells exhibit immunosuppressive effects by interacting with T cells, and this reduces brain inflammation and disease severity (11, 12) . Obviously, the exact mechanisms involved with ameliorating COmediated brain injury are unclear and will require further study.
Hg) and longer-lasting (148 vs. 89.5 minutes) reductions of ICP in patients with severe TBI. A somewhat larger study by Munar et al (13) showed that HTS boluses in the first 72 hours after injury cause a significant increase in serum osmolality with a resultant decrease in ICP. In a study of fluid resuscitation of multitrauma patients with severe TBI, Vassar et al (19) found that administration of HTS (rather than lactated Ringer's) significantly improved patient survival (34% vs. 12%). Although a cohort analysis by Wade et al (20) demonstrated significant improvement in survival in patients resuscitated with HTS following TBI, a study by Cooper et al (18) of 229 patients with TBI reported improved ICP and cerebral perfusion pressure but no difference in survival with bolus HTS therapy during fluid resuscitation.
In this issue of Critical Care Medicine, Froelich et al (21) investigate the safety of continuous hypertonic saline (CHS) as a maintenance fluid in 187 patients with spontaneous intracerebral hemorrhage (49%), stroke (35%), or TBI (16%). Patients with a Glasgow Coma Scale score Յ8 were treated for at least 5 days with 2% or 3% saline for at least 24 hours (mean 6 days). The average age of patients was 60.4 years, and the study included 86 women and 101 men. The decision to treat with CHS was based on "physician preference." The authors found that CHS significantly increased the risk of both moderate (Na Ͼ155) and severe (Na Ͼ160) hypernatremia, but did not significantly increase the risk of renal dysfunction, deep vein thrombosis, or infections. The authors conclude that CHS therapy is safe in the neurocritical care setting as long as patients are carefully monitored for hypernatremia.
This represents one of the largest clinical series on the role of HTS in primarily nontraumatic neurocritical care patients. To date, there are four published trials of HTS in subarachnoid hemorrhage, two case reports on its use in spontaneous intracerebral hemorrhage, and two small series of HTS for ischemic stroke [see Forsyth et al (22) ]. In the neurotrauma literature, studies of CHS are primarily focused on pediatric patients (23) (24) (25) where this strategy has been shown to significantly improve ICP control. In adult studies, however, the literature is limited to retrospective reports that have failed to demonstrate persistent improvements in ICP control or neurologic outcome. For example, Qureshi et al (26) found that CHS therapy transiently improves ICP, but is sometimes followed by rebound intracranial hypertension. In a subsequent publication, these authors found no improvement in neurologic outcome with CHS therapy (27) . The report by Froelich et al (21) , therefore, is novel in suggesting that CHS may be safe across a spectrum of adult neurocritical care pathologies.
Certain aspects of this study, however, limit its impact on the CHS literature. For example, there is significant selection bias in this study, and it is unclear how decisions were made to start, perform, and wean HTS infusions. There are no data provided on the effects of CHS on ICP management, and it is unclear whether the 3.5-fold increased incidence of ICP elevation was due to treatment or group selection. Because of its nonrandomized nature, treatment groups were significantly different with respect to age, initial ICP, blood urea nitrogen, and neurologic diagnosis, and it may not be appropriate to combine data from patients with spontaneous intracerebral hemorrhage, stroke, and TBI. In the trial by Qureshi et al (26) , ICP-lowering effects were only present in patients with TBI and postoperative cerebral edema, whereas those with spontaneous intracranial hemorrhage or stroke (which represents 84% of patients in the study by Matteus et al) did not experience benefit from this therapy.
Although Matteus et al (21) found no significant relationship between CHS therapy and adverse effects, their data raise some concern over the use of CHS in neurocritical care patients. CHS therapy was associated with increased number of infection days and longer hospital stays and strongly correlated with the development of moderate and/or severe hypernatremia. Hypernatremia significantly increased the risk of renal dysfunction and showed strong trend toward increased incidence of deep vein thrombosis. These results underscore the authors' recommendation that patients receiving CHS therapy be closely monitored for iatrogenic hypernatremia.
The effect of CHS therapy on neurotrauma patients in this study is difficult to interpret, because only 16% of patients had TBI and the population studied was significantly different from typical TBI demographics (age 60 years, 46% women). Subgroup analysis was not performed with respect to diagnosis; therefore, it is unclear if the minority of patients with TBI experienced differential responses to CHS therapy. To determine whether CHS is beneficial in preventing secondary oligemia and ischemia after TBI, information on therapeutic intensity level for ICP control, brain tissue oxygenation, and/or microdialysis values would be extremely useful.
In summary, HTS is a powerful tool for acute management of elevated ICP, and it may have a beneficial role in the resuscitation of neurotrauma patients in shock. Its role as a continuous infusion in the neurocritical care setting, however, is less clear and cannot be recommended at this time. Prospective, randomized clinical trials that control for dosing, duration, weaning, and specific neurologic pathology are needed to further investigate the safety and efficacy of CHS in neurocritical care management.
J. Paul Muizelaar, MD, PhD Kiarash Shahlaie, MD, PhD Department of Neurosurgery University of California-Davis School of Medicine Sacramento, CA Multimodal magnetic resonance imaging for determining prognosis in patients with traumatic brain injury-Promising but not ready for primetime* A ccurately determining prognosis in patients with brain injury remains a significant challenge for intensive care physicians worldwide. Outcomes with certain neurologic injuries are somewhat easier to predict, such as massive or eloquently located ischemic strokes or intracerebral hemorrhages, in which it is often clear that, even if the patient survives, they will be left with a severe and often unacceptable level of physical and/or cognitive im-pairment. Global anoxic brain injury, such as from cardiac arrest, is a much more homogeneous process affecting many brain regions simultaneously. Yet, even for this type of injury, we are only able to accurately predict poor prognosis with very low false-positive rates for patients who fit into rather strict criteria, and neuroimaging is not included among the validated assessment tools (1) . Traumatic brain injury (TBI) is an even bigger prognostic problem. Part of the difficulty lies in the fact that TBI is a very heterogeneous disease. Brain injury can occur due to external compression of brain (e.g., epidural or subdural hematomas), primary parenchymal damage (e.g., diffuse axonal injury or brain contusions), or secondary injuries (ischemic insults caused by poor cerebral perfusion, central nervous system infections, or toxic metabolic effects). Furthermore, concomitant systemic injuries and subsequent complications are very common in TBI, further complicating the picture. However, TBI commonly affects younger age groups, and these patients may achieve surprisingly good outcomes despite initially appearing to have quite dismal prognoses. To accurately predict outcome with TBI, all of this needs to be taken into account, and efforts should be made to predict prognosis with a high degree of certainty, ensuring that no patients are predicted for a poor outcome who may yet have a meaningful survival.
Studies to date have focused on the neurologic examination (2), biomarkers (3), and electrophysiology (4) to aid in the prediction of outcome for patients with TBI, but none has given entirely satisfactory data. Despite the great ad-Recognizing rehabilitation resource needs: Role of critical care practitioners* C hildren with "special healthcare needs" are those who have chronic physical, developmental, behavioral, or emotional conditions that impart activity limitations and need ongoing health and related services of a type and quantity that is well beyond service requirements of typically developing children (1) . By definition, these children require additional, individualized health resources as they interface with the health system, whether for a new acute health issue or an ongoing chronic problem.
In this issue of Critical Care Medicine, Cremer et al (2) addresses an important and timely issue regarding the rapidly growing number of children who are admitted to pediatric intensive care units (PICU) with a preexisting chronic health condition or disability. Critical care practitioners from within an international network of health centers in Frenchspeaking regions were surveyed regarding the prevalence of chronic conditions and disability among children admitted to their PICU. In addition, the PICU physicians' perceived needs of rehabilitation services on two separate days and actual rehabilitation resources provided to their patients on those days were also appraised. The findings provide two important take-home messages. First, twothirds of children admitted to 23 Newborn and Pediatric ICUs had chronic health conditions with or without disabilities. Disability, broadly defined using the Pediatric Overall Performance Category (3), was evident in about half (49 of 102) of these children. These results support existing preliminary studies that demonstrate that a substantial subset of children who require intensive care have premorbid chronic health and developmental concerns. Indeed, for neonatal ICUs, the majority of survivors are also expected to have chronic health conditions and/or developmental disabilities. Second, the perception of intensivists participating in this study was that there were critical gaps between rehabilitation service needs and actual service provision, particularly, with reference to neuromotor (e.g., to improve motor patterns, prevent contractures) and oromotor (e.g., swallowing, speech) interventions. To my knowledge, this is the first study that provides empirical evidence of unmet rehabilitation resource needs in the PICU population. Services, when provided, were predominantly directed at improving respiratory capacity, and the primary specialist implicated in the Newborn and Pediatric ICUs surveyed was Physical Therapy, with a lack of intensive involvement by other rehabilitation specialists.
Advances in medical and surgical care have resulted in a dramatic decline in pediatric mortality rates and in enhanced identification and management of children with a variety of health conditions. Chronic health conditions are medical illnesses of lengthy duration (typically, at least 12 months) that involve one or more organ systems (4). A recent systematic review concludes that prevalence rate for these conditions is highly variable, ranging from Ͻ1% to 44% depending on the operational definitions used, but is nonetheless increasing (5) . These chronic health conditions share common attributes to include an ongoing, often lifelong need for medical and therapeutic services, greater family support service needs, and limitations in functional status (6). These activity limitations or "childhood disabilities" have an estimated population prevalence of 7% to 8% (7, 8) . The high proportion of children admitted to ICUs with chronic health conditions and disabilities highlighted in the study by Cremer et al has important immediate implications for practice for critical care physicians. Children admitted to PICUs with chronic health conditions and disabilities require additional management of complex needs, skillful care planning in the ICU and at discharge, and specialized child and family support services. Therefore, the medical team must recognize this growing requirement for additional interdisciplinary resources and thus advocate for appropriate and adequate consultation and involvement of rehabilitation professionals as part of multifaceted acute care services.
Children admitted with chronic health conditions and disabilities require specialized rehabilitation service requirements; however, children who had no preexisting health conditions may also require rehabilitation support and followup, particularly if at risk for subsequent developmental sequelae. For example, children with traumatic brain injuries, near-drowning, or encephalitis are at high risk for long-term disability and therefore also need specialized rehabilitation assessments and interventions beginning acutely. In the PICU setting, rehabilitation professionals can provide additional expertise to the interdisciplinary team, to include, for example, modulating behavioral state and stress responses, positioning and handling techniques to prevent contractures and maintain mobility, enhancing respiratory capacity, facilitating coordinated swallowing and safe and effective feeding, promoting sensory responsiveness and developmental acquisitions, providing necessary adaptive equipment, anticipating emergent home and communitybased service needs, and educating and supporting highly stressed families. There is a paucity of literature on the roles and responsibilities of rehabilitation specialists in PICUs; however, there have been a number of studies that elucidate their respective roles in neonatal ICUs (9 -12) .
Ultimately, critical care practitioners should work collaboratively to develop standards and guidelines for rehabilitation referral so as to optimize service utilization. Indeed, recent guidelines for levels of care in the PICU indicate that rehabilitation professionals (e.g., physical therapy, occupational therapy, speech language pathology, psychology, social work) should be members of the critical care team and available for consultation and intervention (13) . However, specific indicators for referral are lacking and warrant elaboration in the future. It is likely that current practice in PICUs and neonatal ICUs is largely influenced by institution-specific rehabilitation expertise that is locally available (11) and the efforts made by particular disciplines to advocate for their specialized roles and potential contributions to the ICU team. For example, occupational therapists have published guidelines of specialized knowledge and skills necessary for practice in neonatal ICUs (14) , and indeed they are intensely implicated in service provision in ICUs in North America (11, 14) .
Future studies are needed that focus on rehabilitation resource utilization patterns in other regions, with clarification of discipline-specific roles and functions. To develop practice guidelines based on evidence, research studies need to provide empirical data to support the effectiveness of and satisfaction with these rehabilitation services in Newborn and Pediatric ICUs, in meeting the specialized needs of this population of interest (12) . Nonetheless, the demographic profile of children admitted to PICUs is rapidly changing to include infants, children, and youth with chronic health conditions and disabilities. Therefore, critical care practitioners need to recognize, value, and address the growing need for rehabilitation services as part of the ICU care of these children. With their advocacy and support, current gaps in service delivery may be addressed so as to optimize resources, thus promoting a more holistic, comprehensive approach to the critical care of the child and family with special needs. These interdisciplinary efforts are ultimately aimed at maximizing the health and long-term functional outcomes of this high-risk population.
Annette Majnemer, OT, PhD School of Physical and Occupational Therapy McGill University Montreal, Quebec Canada Trying to make sense of the intangible: Reading qualitative studies* I mproving health care is a complex process. The government invests a considerable number of resources into understanding the mechanism of disease and identifying the therapeutic options that provide the best treatment. Therefore, it is disappointing when innovative clinical practices do not produce as positive an effect as scientists predicted. Part of this shortfall can be attributed to the effect that social phenomenon has on the delivery of health care. This has been one of the most elusive aspects of understanding how therapeutic interventions affect populations. There is more to consider than simply which drug to give and in what dose. Even the strictest treatment protocols are modified according to the social context of the physician and the patient (1). These are very compelling arguments that highlight the need to understand all the elements that affect medical decision making and therefore patient outcome. Healthcare scientists have shown an increasing interest in analytic tools that are meant to study how social life in its natural uncontrolled form affects medical care (2) . This growing interest is reflected in the increasing number of qualitative studies that are published in medical journals. Although most researchers understand the importance of this issue, they quickly become lost in a sea of unfamiliar concepts and language when reading and appraising studies about social interactions and context (3) .
The greatest hurdle for most scientists is trying to figure out whether a qualitative analysis is a good or a bad study. A significant problem is that methods used to appraise a quantitative study cannot be applied easily to qualitative analysis (4). This often causes researchers who have been educated in deductive-based quantitative sciences to reject a qualitative study as being "soft science" or without substance. It would be easy to say that the only reason quantitative scientists hold this opinion is simply because they are not educated in qualitative methodology. However, the differences between the theoretical frameworks of both disciplines can be so large that these scientific traditions seem to have a cultural rift.
All quantitative research aims to ensure that the findings of any study can be repeated in a variety of circumstances and produce the same results. This assumes that there is a single reality or truth, which can be discovered by appropriate techniques (1) . A study is judged as valid if it approximates this truth. The theoretical framework for designing these types of experiments is called positivism, and this single approach unifies numerical-based studies. There are some qualitative researchers who create similar theoretical frameworks from an objective paradigm called realism (5) . However, at the other end of the spectrum, there are equally as many qualitative scientists who do not think that there is a single underlying reality and theorize that we cannot know the true nature of the object world or separate our perceptions from it. In this view, realities are multiple and fluidlike. This is termed interpretivism. Between these two polar positions are a gradient of beliefs that are expressed in the methodology of qualitative analysis.
The scission in paradigms that exist in qualitative research requires investigators from various theoretical frameworks to use different yardsticks to measure how good a study is. Quantitative scientists often underestimate this obstacle when critically appraising qualitative work. Just when they think, "ah now I understand," another article appears exposing a different paradigm for analysis. The changing theoretical paradigms in qualitative research are not a limitation of the specialty. In fact, most social scientists would argue that multiple viewpoints enhance the overall understanding of social interactions. Albert Einstein captured the confusion about theoretical frameworks very well when he said "Whether the chicken crossed the road or the road moved beneath the chicken depends on your frame of reference" (6) . But, the various theoretical and analytic approaches to qualitative research make it very difficult for most health care scientists to identify a good study. In this issue of Critical Care Medicine, Giacomini et al (7) presents a substantial review of published qualitative literature on the topic of "decision-making about life support." The objective of the investigative team was to "identify and appraise" qualitative studies on this topic. The title and objective raised considerable hope that Giacomini et al would provide a few simple secrets of how to sort the good from the bad. However, the study fails to translate "qualitative research talk" into principles that numerical scientist can use. The investigators collected and appraised journal and text articles on the topic of "decisions about life support." The criteria that the investigative team used for their appraisal were intentionally broad even in qualitative terms. They seem to have chosen this classification so that they could extend their analysis to research studies from a variety of theoretical frameworks.
Most would find it difficult, however, to accept that any single yardstick could measure the quality of studies that are based upon different interpretations of reality. The authors acknowledge this point but then proceed without incorporating this modifier into their analysis. For example, the investigative team argues that a study is good if "the choice of participants or observations is explicit" and the "participants are chosen purposively." But, who judges the purpose and in what theoretical framework? In contrast to the overly broad classification by the investigative team, qualitative researchers who use realism paradigms would measure quality by different
